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Abstract 
MARKOV CHAIN MONTE CARLO IN GENETICS: SUBPHENOTYPING, 
LINKAGE DISEQUILIBRIUM MODELING, AND FINE MAPPING 
by 
Ziqian Geng 
 
Chair: Sebastian Zöllner 
The advance of modern genotyping and sequencing technologies makes large scale data 
available in different genetic studies. Meanwhile, MCMC algorithm provides powerful 
computational tools in handling these high-dimensional genetic data. In this dissertation, 
I demonstrate several MCMC applications in emerging genetic studies. 
In Chapter 2, I propose a method to identify genetically homogeneous subphenotypes of 
complex diseases. I assume that different disease subtypes, caused by different risk 
variants, behave uniquely in clinical characteristics (treated as covariates). I design an 
algorithm to identify these covariates to define genetically homogeneous subtypes. 
Conditional on these covariates, this algorithm calculate each affected individual’s 
posterior probability of belonging to each subtype. Using simulated data, I illustrate that 
my algorithm correctly identifies subtypes, such that affected individuals within each 
subtype group are likely to carry the same risk variants. I also evaluate whether 
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stratifying on these estimated subtype memberships improves the power to detect 
phenotypic association at risk loci attributable to these subtypes.  
In Chapter 3, I introduce a novel algorithm to model the linkage disequilibrium (LD) 
between different genomic positions through shared genealogies. Compared to traditional 
hidden Markov models (HMM) which might over simplify the evolutionary process of 
sampled haplotypes, my method allows for more variations in prior probabilities about 
shared haplotype segments descend from particular ancestors, as well as more variations 
in population genetic parameters. Through this more careful model, our method improves 
the accuracy in haplotype reconstruction. Moreover, I propose a fine mapping algorithm 
based on this model to localize complex trait loci. My algorithm identifies disease causal 
loci accurately when traditional mapping approaches based on single marker tests have 
low power. 
In Chapter 4, I propose an approach to overcome the computational burden in fine 
mappings using our coalescent-based modeling. I first estimate a set of clusters of 
sampled haplotypes such that members within each cluster share one common ancestor. I 
then make inferences about genealogies of these clusters to localize candidate regions of 
disease-causing mutations. Using simulated data, I illustrate that this implementation 
enables my fine mapping approach in large samples with several tens of thousands of 
individuals. 
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Chapter 1 Introduction 
In recent years, genetics studies involve high dimensional data analysis. In a typical 
genome-wide association study (GWAS), millions of variant sites are genotyped and 
analyzed to detect candidate regions associated to certain phenotypes of interest. Along 
with the development in next-generation sequencing technology, genetic data to be 
analyzed contains even higher dimensions of variables. Consequently, many statistics of 
interest in modern genetic studies cannot be calculated analytically. 
To approximate these statistics of interest from high-dimensional data, Markov chain 
Monte Carlo (MCMC), as a powerful computational tool in Bayesian modeling, is widely 
applied in modern genetic studies. Conditional on the observed phenotypes and 
genotypes, as well as the family structures of sampled pedigrees, MCMC algorithms pick 
a large number of random draws from the Markov chain to approximate the posterior 
distribution of statistics to be analyzed. During the late 1990s and early 2000s, several 
MCMC approaches have been developed in linkage studies to explore different 
perspectives of genetic questions, such as what individual in large pedigrees should be 
genotyped and analyzed (e.g., Fernández et al. 2001; Tier and Henshall 2001), and what 
loci are attributive to the quantitative trait of interest (e.g., Heath et al. 1997; Uimari and 
Hoeschele 1997; Daw el al. 1999). More recently, MCMC algorithms have also been 
applied to association studies using population genotype data of unrelated individuals. 
Multiple MCMC-based approaches have been developed to model the linkage 
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disequilibrium (LD) in genomic regions and to make inferences about population genetic 
parameters (Nielsen 2000; Fearnhead and Donnelly 2001; Morris et al. 2003). 
Although promising, traditional MCMC approaches require large amount of 
computations to approximate the posterior probability of interest. To reduce this 
computational intensity, Li and Stephens have developed a method using hidden Markov 
models (HMM) to approximate LD and to identify recombination hotspots (Li and 
Stephens 2003), which has been proved an computationally efficient model. In recent 
years, similar HMM approaches are widely applied to other LD-based studies, such as 
haplotype reconstruction (e.g., Stephens and Donnelly 2003; Scheet and Stephens 2006) 
and genotype imputation (e.g., Marchini et al. 2007; Browning and Yu 2009; Li et al. 
2010; Howie et al. 2012). 
In this Chapter, we give an overview of MCMC methods in subphenotyping for complex 
diseases, as well as in modeling linkage disequilibrium and in mapping of complex trait 
loci. 
1.1 Sampling genetically homogeneous subphenotypes 
Genetic heterogeneity is one of the major challenges for identifying complex trait loci. In 
many cases, we observe multiple genetic variants affecting the same phenotype – each 
with a relatively small effect size. Accordingly, the power to detect every single variant’s 
association to the phenotype is reduced when affected individuals carrying different risk 
variants are collected into one sample of cases. Indeed, creating genetically more 
homogeneous subtypes of cases, would increase some risk allele frequencies in these 
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subtype samples, and thus improve the power to detect phenotypic association at relevant 
risk loci. 
Since the underlying risk variant is priori unknown, subtype strategies are valid only if 
non-genetic indicators for the underlying genetic variants are available. Several studies 
have hypothesized that different risk variants affect the same disease endpoint through 
different pathways, such that they create differences in clinical characteristics 
(Burmeister et al. 2008; Saunders et al. 2008; Saunders et al. 2009). These clinical 
behaviors, correlated with different risk variants, are then treated as covariates to define 
different subtypes of the disease in many studies. 
While defined subphenotypes can increase the risk variant frequency within each 
subphenotype sample, they also reduce the sample size of affected individuals within 
each subtype sample. Hence, the power gain from genetic homogeneity must outweigh 
the power loss from sample size reduction (Burmeister et al. 2008; Morris et al. 2010). 
Various subphenotype approaches have been implemented in recent years. Most 
commonly, subphenotypes are defined by stratifying affected individuals on single 
observable traits (e.g., Zandi et al. 2007; Lydall et al. 2009). However, single covariate 
stratification is less efficient when genetic variants weakly affect many covariates. To 
define subphenotypes by analyzing multiple covariates, different approaches have been 
proposed in recent years. Most of these approaches are either based on known 
comorbidity information (e.g., Schulze et al. 2006; Morris et al. 2010) or pre-selected 
SNPs (e.g., Wen and Lu 2013); they are thus not generalizable to other complex disease 
studies. 
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In Chapter 2, we propose a novel approach to define genetically homogeneous sample of 
subphenotypes that are generalizable to any complex disease. This approach analyzes the 
segregation in a large set of covariates, and identifies subsets of co-inherited covariates 
attributable to the same risk variants to identify sub-samples of cases more likely to carry 
the same risk variants. 
1.2 Modeling of linkage disequilibrium 
By definition, LD is the dependence structure of alleles carried at different positions in 
the genome. Modeling of LD is crucial in many aspects of genetic studies. In practice, 
LD provides valuable information about which alleles, at different loci, are inherited 
together. In recent years, many widely used software packages, such as PHASE 
(Stephens et al. 2001; Stephens and Donnelly 2003) or MaCH (Li et al. 2010), are 
modeling LD based on an HMM algorithm (Li and Stephens 2003): At each genomic 
position, the observed state is the genotypes and the latent state is which ancient 
haplotype in the target population is the observed haplotype descends from.. Conditional 
on the hidden state, the observed genotypes can be modeled as imperfect copies with 
mutations at each site. The algorithm then models the whole genomic region site-by-site 
as a Markov process, where the transition probability between neighboring sites is 
modeled through recombination rates. 
Although successfully applied in many studies, the HMM algorithm oversimplify the 
latent inheritance pattern. Typically, it assumes uniform prior probabilities that each 
sampled haplotypes are equally likely to be descendant of any haplotypes within the same 
 5 
 
target population. In genomic regions where too many mutation and recombination 
events have resulted in much complicated inheritance patterns, we observe reduced 
performance when applying these oversimplified HMM algorithms. Likewise, we also 
observe reduced performance when applying HMM algorithms to individuals sampled 
from admixed populations. 
Alternatively, several studies have focused on making inferences about the evolutionary 
history of sampled individuals, to model LD through the shared genealogy within short 
genomic segments that are inherited together (e.g., Zӧllner and Pritchard 2005; Burkett et 
al. 2013b). Compared to the HMM algorithm which assume uniform prior probabilities of 
inheritance from a “pool of haplotypes”, these coalescent-based methods quantify the 
sampled haplotypes’ probability of descending from different ancestors based on the 
estimated local ancestry of sampled individuals. Moreover, coalescent-based methods 
analyze different positions in parallel, thus allowing more variability in mutation rates 
and recombination rates across genomic regions of interests. For each co-inherited short 
segments in the studied genomic region, these methods provide more careful local LD 
modeling. 
However, coalescent-based methods are computationally extremely intensive when 
making inferences about genealogies. To reduce computational intensity, existing 
coalescent-based methods typically assume first or second-degree Markov model to 
approximate the construction of sampled haplotypes. This simplification ignores the LD 
between more distant loci, and is thus not applicable in studies using high density SNPs. 
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In Chapter 3, we propose a more careful model of LD, which combines the local 
genealogy from coalescent-based model with the more distant modeling of haplotypes 
using HMM. To demonstrate that our algorithm provides more accurate model of LD 
than traditional methods, we apply our algorithm to an LD-related study, haplotype 
reconstruction. According to our simulation studies, haplotypes are more accurately 
reconstructed based our LD modeling than based on traditional HMM algorithms. 
1.3 Mapping of complex trait loci 
According to the Catalog of Published Genome-Wide Association Studies 
(http://www.genome.gov/gwasstudies), GWAS have identified over 1,500 genomic 
regions associated with hundreds of phenotypes. However, most of variants found by 
GWAS are located in regions that lack obvious functional consequences. These results 
are not surprising, as the idea of GWAS is based on the assumption that at least some 
detected associations are due to high LD between the tested SNPs and the non-genotyped 
true causal variant site, to identify a set of candidate regions for follow-up studies about 
functionalities.  
This ambiguity in detected associations can be partly solved by whole-exome sequencing 
studies, where the association at true causal site is directly tested. However, the causal 
site is not always genotyped even using sequencing data: it can be filtered due to low 
quality in low coverage sequencing; or the causal mutation may be not a variant but an 
indel or a copy-number variation (CNV), or it may be a non-coding functional variant. 
Moreover, many studies are based on imputation-based analysis to detect rare to low-
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frequent variant associations (Servin and Stephens 2007; Guan and Stephens 2008; Li et 
al. 2010). Although promising, rare variant association studies still face the challenge that 
some rare causal variant may be incorrectly imputed when it is not observed in the 
reference panel for imputation. In all these situations where causal variant is non-
genotyped, traditional approaches will have reduced power to detect the phenotypic 
association at the causal loci. And the follow-up fine-scale mapping can be biased. 
Alternatively, several studies have focused on mapping candidate regions through 
estimating the evolutionary history of causal mutations (Morris et al. 2002; Zӧllner and 
Pritchard 2005; Tachmazidou et al. 2007, Burkett et al. 2013a). Based on the coalescence 
theory, these methods analyze the genealogy between cases and controls position by 
position, to locate candidate regions harboring disease causal mutations. These methods 
jointly analyze genotypes at surrounding sites to make inferences about the genealogy. 
They are thus more powerful in studies where traditional approaches based on single 
marker tests have low power, and are more robust to the scenario when genotype is 
missing at a single causal position. 
In Chapter 3, we improve traditional coalescent-based model of LD by an HMM 
algorithm such that it can be applied to studies using high density SNPs. We then propose 
a fine-mapping approach based on this HMM-enhanced model to locate complex trait 
loci. Using simulated data, we demonstrate that our method correctly identifies candidate 
regions harboring causal variant sites. We also illustrate that our algorithm performs 
more robustly when genotypes at causal sites are missing, compared to traditional fine 
mapping algorithms based on initial sets of candidate regions with GWAS-detected 
associations. 
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In Chapter 4, we design a novel coalescent-based algorithm for fine mapping, which 
utilizes a clustering method (Scheet and Stephens 2006) to reduce the sampling space of 
genealogy inferences. Using simulated data, we illustrate that our implemented algorithm 
correctly identifies credible regions harboring causal variants in large-scale studies with 
several thousands of sequenced individuals.  
1.4 Outline of dissertation 
In this dissertation, we describe several MCMC algorithms that address different 
statistical genetic challenges. This dissertation is organized as follows: In Chapter 1, we 
give an overview about our dissertation. In Chapter 2, we describe our algorithm which 
identifies affected individuals carrying the same risk variants through analyzing the 
segregation of a large set of observable covariates. In Chapter 3, we focus on our HMM-
enhanced coalescent-based modeling of LD, which improves the accuracy of haplotype 
reconstruction and can be applied to correctly mapping candidate loci of complex traits. 
In Chapter 4, we implement a clustering method to our coalescent-based model, such that 
our new method is capable in large-scale studies to identify candidate regions for 
complex trait loci. In the end, we provide a summary of our studies in Chapter 5. 
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Chapter 2 A covariate based affected sib-pair endophenotype sampler 
in association studies 
2.1 Introduction 
Recent years have seen substantial progress in understanding the genetic basis of 
common complex diseases. Combining studies to achieve massive sample sizes 
(Thornton and McPeek 2010; Wen and Stephens 2010) reveals that common risk variants 
typically have very low effect sizes and each variant explains only a small proportion of 
the total heritability in many diseases. Identifying further genetic factors for complex 
traits remains a major challenge in human genetics (Hirschhorn and Daly 2005; 
McCarthy et al. 2008), which will require even larger sample sizes. Meanwhile, rare 
variants are now targeted as promising candidates for the missing heritability not 
explained by common variants. However, rare variant studies also require very large 
sample sizes to be adequately powered (Zöllner 2012; Nelson et al. 2012). 
The large sample size requirement can be at least partly explained by the genetic 
heterogeneity of the studied phenotype. In many cases, we observe multiple genetic 
variants affecting the same phenotype – each with a relatively small effect size. 
Accordingly, the power to detect every single variant’s association to the phenotype is 
small when patients carrying different risk variants are collected into one sample of cases. 
Indeed, creating genetically more homogeneous sample of cases, would increase some 
risk variants’ allele frequencies in this sample, and thus improve the power of detecting 
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these variants in association studies. As the underlying risk variant is priori unknown, 
such stratification is only possible if non-genetic indicators for the underlying genotypes 
are available. Such indicators can be identified if different risk variants affect the same 
disease endpoint through different pathways, and thus create differences in clinical 
characteristics (clinical heterogeneity). These clinical characteristics (treated as 
covariates) are then correlated with different risk variants (Burmeister et al. 2008; 
Saunders et al. 2008). Properly picked covariates will then contain information about the 
underlying genetic heterogeneity, and may define genetically more homogeneous 
subtypes of the disease. 
We borrow the endophenotype approaches suggested by many psychiatric studies, to 
identify genetically more homogeneous subtypes of a disease (Gottesman and Gould 
2003). While endophenotype approaches can increase the risk variant frequencies within 
cases with the same subtype, it also reduces the sample size of cases to the subset of cases 
showing this subtype. Hence, the power gain from genetic homogeneity must outweigh 
the power loss from sample size reduction (Burmeister et al. 2008; Morris et al. 2010). 
Various endophenotype approaches have been applied to study different psychiatric 
diseases and other complex diseases (Gottesman and Gould 2003; Flint and Munafo 
2007). Most commonly, this idea is applied by stratifying affected individuals on single 
observable traits (single covariate stratification). For example, stratification by age of 
onset showed the relation between certain genotypes and early onset Alzheimer’s disease 
is stronger than between the same genotypes and late onset Alzheimer’s disease (Dizier et 
al. 2012; Velez et al. 2013). Likewise, several studies for bipolar (BP) disorders stratified 
affected individuals on comorbid symptoms (Willour et al. 2007; Zandi et al. 2007; 
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Lydall et al. 2009; Saunders et al. 2009; Kerner et al. 2011), to identify variants 
associated with BP that are not reported before. In general, single covariate stratification 
is most powerful if only one genetic variant has a strong effect on the covariate. It is less 
efficient if genetic variants weakly affect many covariates, because stratifying on one 
covariate now insufficiently increases the allele frequency of any risk variant. In this 
latter situation, stratifying on multiple covariates simultaneously may identify individuals 
carrying specific risk variants. However, doing so will divide the whole sample of 
affected individuals into many small subsets (Burmeister et al. 2008; Morris et al. 2010). 
Such quick sample size reduction will result in an unrecoverable power loss. Therefore, 
an applicable approach to analyze multiple covariates for endophenotypes, which does 
not generate a hard limit on the number of individuals within each subtype, becomes a 
necessity. 
In recent years, several advanced approaches based on multiple covariates have been 
developed to define endophenotypes for complex diseases. For instance, Schulze et al 
(2003) proposed a mixed-effects regression analysis on BP with 40 phenotypic features. 
Andreassen et al. (2013) increased the power to detect common variants associated with 
schizophrenia by leveraging comorbidity risk factors of cardiovascular diseases using a 
stratified FDR method. And Morris et al. (2010) proposed a multinomial regression 
framework to allow for genetic heterogeneity between subtypes. However, these methods 
assume known comorbid and pleiotropic information to pre-select a few covariates. They 
are not generalizable to studies of other diseases where comorbidity is not well studied. 
Alternatively, Wen and Lu (2013) recently proposed a method which does not rely on 
known comorbidity, but focuses on selecting the optimum number of subtypes contained 
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in sampled cases. However, their model selection is based on selected SNPs. It is only 
applicable to confirm known candidate loci rather than exploiting new gene-phenotype 
association. Finally, principal component analysis (PCA) is also applied to define 
endophenotypes in complex diseases (Wang et al. 2009). However, it is difficult to 
distinguish whether the PC-represented subtypes are truly driven by underlying genetic 
variants, or are merely artifacts due to some highly correlated, non-heritable factors. 
In present study, we propose an algorithm based on the similar intuition as PCA: we 
assume that each subtype, represented by differences in covariates, is attributable to the 
constellation of one or more genetic variants. We then study the correlation structure 
between the set of covariates to identify affected individuals belonging to these subtypes 
in the study sample. Unlike PCA, our method identifies heritable subtypes by modeling 
the heritability in related individuals – if truly heritable due to genetic variants, covariates 
representing these subtypes are more likely to be shared within each family than between 
unrelated individuals (Freimer and Sabatti 2004). Indeed, we model this sharing pattern 
of covariates to calculate every affected individual’s posterior probability of being 
affected by each subtype, conditional on the set of covariates. We use this posterior 
probability to prioritize individuals carrying the same risk variants. We implement our 
algorithm for sibling-pairs – a Covariate-based Affected Sib-pair Endophenotype 
Sampler (CASES). 
To test CASES, we simulated sib-pair datasets in which at least one sibling is affected by 
a dichotomous phenotype. For a wide range of disease models, we simulated one or more 
risk variants which also associated with different sets of covariates. We analyzed these 
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covariates using CASES to identify subtypes among the cases and to evaluate if the 
subtypes represent the underlying genotypes at the risk loci. 
Our results show that our algorithm successfully identifies the informative subset of 
covariates from other covariates not affected by the underlying risk variants. Based on 
these covariate subsets, we successfully identify individuals carrying the same 
endophenotype, who are more likely to be carrying the same risk variants. We then 
illustrate that using these endophenotypes is helpful in guiding the sampling of affected 
individuals carrying specific risk variants. The precision of endophenotype identification 
increases with the increased effect sizes and increased number of co-inherited covariates. 
Moreover, we are able to use this defined endophenotypes to improve the power in 
association studies. 
2.2 Methods 
We propose an algorithm that estimates each affected individual’s probability of carrying 
any subtype of the disease. We model each subtype as attributable to a set of risk variants 
which also affect a set of distinctive covariates. 
We consider a sample of  families; each family contains at least one affected individual. 
Moreover, every family member is measured for a set of   covariates in dataset . We 
use  as the unknown number of subtypes and  to denote the unknown genotypes at the 
risk loci affecting different subtypes. We will discuss the selection of  later. The risk 
allele frequency , variant effect sizes , and the between-covariate effects 	 are also 
unknown and to be estimated in our algorithm (Table 2.1) 
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2.2.1 Data structure 
We observe  covariates in dataset  for each individual. These covariates can be either 
dichotomous or continuous, and are observed in dataset . We denote 
 = [
, … 
] 
to represent the vector of covariates in family  of size . Let 
 represent the affection 
status (phenotype) of family member  in family , where 
 = 1 for all  = 1,2, …  
since we condition on at least one affected individual per family. We use 
 to denote 
the observed covariate  ( = 1,2, … ). 
We model   risk variants affecting   subtypes. For family  , let 
 = [
, … 
] 
denote the unknown genotypes at these risk loci in , where 
 = [
, … 
] are 
the underlying genotypes in family member  ( = 1,2, … ). 
2.2.2 Models 
Ultimately, our goal is to estimate each affected individual’s probability of belonging to 
each subtype. Under our assumption, this is equivalent as estimate the probability of 
carrying each risk variant, as in |. By Bayes rule, it is proportional to 
| ∝ | ∙  
First, we specify the covariates model | and model the co-inheritance pattern in 
covariates. We assume multiplicative models. For each member   in family  , the 
phenotype probability follows logistic models: 
#$%& '(
)
, 
* +, = 
 + 	
* , 
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where  = [, , … ] are risk variant effect sizes on the studied phenotype and 
 is the baseline phenotype risk. Similarly, 	 = [	, … 	/] are the other covariates’ 
effects on the phenotype, which models the between-covariate correlation not explained 
by genetic variants. 
We assume similar multiplicative models for all covariates. Let  and 	 denote the risk 
variants’ and other covariates’ effect sizes on covariate  with baseline level . We use 
logistic regression to model any dichotomous covariate: 
#$%& '(
)
 , 
* +, =  + 	
* . 
For continuous covariates, we substitute linear regression models. Overall, the joint 
probability of phenotypes and covariates in family  , given their genotypes, can be 
written as: 

|
 = 1 1 [
|
, 
* ]  
To calculate , we define  = [, 2, … ] as the unknown risk allele frequencies 
in the target population. We use  to calculate the joint genotype probability 
| 
within each family , based on the relatedness and genotype transmission probabilities 
between members in this family. 
2.2.3 Algorithm 
By Bayes rule, the joint posterior probability of genotypes given covariates in all families 
is proportional to the total likelihood: 
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| ∝ 1 [
|
 , , 	 ∙ 
| ∙  ∙  ∙ 	]
 . 
Specifically, we derive 
|
, , 	  from the previous multiplicative model. Given 
allele frequencies, the marginal genotype probability in each family, 
|, can be 
derived through the kinship coefficient and genotype transmission probabilities between 
family members. 
Furthermore, , , and  	  are prior probabilities of parameters. We choose 
uniform priors on . As we expect that many enrolled covariates are not informative 
about underlying risk variants, many effect sizes in  should be 0. Indeed, we specify the 
spike and slab priors for any effect size 3 as suggested by Ishwaran and Rao (2005) and 
other related studies. We also apply the spike-and-slab priors on 	 , as the prior 
probability of between-covariate correlation unexplained by genetic variants. 
In the present study, we implement our algorithm for sib-pairs in our own software 
(CASES). Accordingly, we model 
|  by integrating over possible identity by 
descent (IBD) status in each sib-pair  (Appendix A). 
Since |  is of high dimensions (  ×  ), we use MCMC to approximate this 
posterior probability. Specifically, we use Metropolis-coupled MCMC to resolve the 
potentially multi-modal posterior distribution in Markov chains. And we use Gelman and 
Rubin diagnostics (1992) to assess the MCMC convergence (see Appendix A for spike 
and slab priors and MCMC details). 
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2.2.4 Simulated data 
For each family, we simulate parental genotypes at  loci based on risk allele frequency 
, assuming Hardy-Weinberg equilibrium. We then generate one offspring genotype and 
assign a phenotype based on this genotype and the risk variant effect sizes in . We 
discard this family if the offspring is unaffected. For families with affected offspring, we 
generate a second offspring genotype and phenotype. We repeat this process until we 
have generated  sib-pairs, each with at least one affected offspring. Given  and 	, we 
then assign  dichotomous covariates to these  affected individuals and their siblings. 
We then mask all genotypes, and use the phenotypes and covariates as the input dataset 
into our program CASES to generate the estimated posterior probability | for these 
 affected individuals. 
2.2.5 Algorithm evaluation 
To evaluate if the estimated | from CASES is informative in identifying affected 
individuals carrying the same risk variants, we compare | to the true genotypes . 
We first rank all affected individuals based on | , and compare if individuals 
carrying genetic risk variants are ranked higher than individuals not carrying these 
variants. We further evaluate the benefit of our algorithm in association studies. Each 
time, we stratify the top-half ranked cases in one vector in |, to formulate a sample 
of cases of one subtype. We compare this sample of cases to a random sample of  
controls from the same population in association tests. At the specific locus attributable to 
each selected subtype, we compute the testing power using our stratified sub-sample of 
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cases under significance level = 5 × 10*7  where the power using all   affected 
individuals is lower than 0.1. 
To evaluate if the subsets of covariates identified by CASES can define genetically 
homogeneous subtypes in other samples of cases from the same population, we design a 
two-step simulation study: 
First, we simulate a sample of  sib-pairs exactly the same as in the previous subsection. 
We then apply CASES to this sib-pair data, to draw a large number (8) of effect size 
estimates 9 and  	9. 
Second, we simulate a second sample of  : unrelated affected individuals, based on the 
same effect sizes as in our first sample of sib-pairs. Conditional on their observed 
covariates, we calculate each individual’s probability of belonging to each subtype based 
on 9 and 	9 in step one by: 
;
|
 = < =
>
, 9, 	9?9  
We then stratify these unrelated affected individuals in this second sample, based on the 
estimated ;
|
, to formulate sub-samples of cases. Comparing each sub-sample of 
cases to a sample of  : controls from the same population, we perform association tests 
at the loci attributable to this subtype. Compared to the traditional association tests using 
all : affected individuals as cases, we evaluate if using sub-samples defined by CASES 
improves the power in association studies. 
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2.3 Results 
To evaluate our algorithm CASES’ ability to identify heritable subtypes, we simulate 
samples of sib-pairs with at least one affected sibling. For each individual, we simulate a 
set of dichotomous covariates affected by unobserved underlying risk variants. We apply 
our program CASES to these covariates to estimate each affected individual’s posterior 
probability of belonging to each subtype. We then stratify cases based on this posterior 
probability to evaluate if we can identify affected individuals carrying underlying risk 
variants attributable to this subtype. 
We initially assume that all covariates are affected by underlying risk variants, and 
different variants are affecting distinctive covariate subsets. Also, we assume known 
number of subtypes . We will relax these assumptions and consider more complicated 
scenarios in the second half of section 2.3.2 and section 2.3.3. 
2.3.1 Discriminating carriers and non-carriers 
We evaluate the resolution of CASES by comparing the estimated probabilities of 
subtype membership to the true genotyeps at risk loci. Initially, we consider the single 
locus model with risk allele frequency 5% and disease OR 1.5. We analyze 200 cases 
with siblings considering 3, 5, 10, or 15 covariates affected by the risk variant, wich 
effect sizes varying between 1.0 and 2.0. 
We rank all 200 cases by their estimated probability of carrying the specific subtype. 
Based on the true genotypes, we compare the mean ranks between cases that carry either 
one or two copies of the risk allele (carriers) and cases that are homozygous with the wild 
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type allele (non-carriers). In all simulated scenarios with covariate effect size greater than 
1.0, carriers have a higher mean rank than non-carriers (figure 2.1A). This difference in 
mean rank increases with more covariates affected by the same variant. Our algorithm 
also better differentiates carriers from non-carriers with an increasing effect size of the 
risk variant on covariates. Overall, including 3 covariates each with an OR of 1.8 has 
about the same effect as including 15 covariates each with an OR of 1.2. 
We also calculated the observed risk allele frequency in top ranked individuals identified 
by CASES (figure 2.1B). For all models, the risk allele frequency decreases from higher 
ranked individuals to lower ranked individuals. Moreover, the ability to identify carriers 
depends on the number of covariates affected by the same risk variant. Specifically, when 
we have more than 15 covariates, more than one third of all carriers within the sample are 
identified within the top 10% ranked affected individuals. If we stratify on the top 10% 
cases, we increase the risk allele frequency within the sample by more than 3 times. 
When we stratify the top half of cases, almost two thirds of all carriers are sampled even 
with only 5 covariates in our model. With increasing stratification size, the observed 
allele frequency reduces towards the expected allele frequency in cases (7.3%), as more 
non-carriers are sampled. In general, CASES correctly identifies carriers conditional on 
co-inherited covariates, which provides an efficient guidance in re-sampling affected 
individuals carrying rare risk variants. 
To illustrate our algorithm performance when more than one risk variants are affecting 
different covariates, we simulated scenarios with 2 risk loci. We analyzed the resulting 
dataset using a model of  = 2 subtypes. As the assignment of clusters to the underlying 
risk variant changes between realizations, we evaluated the performance in multiple 
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realizations by comparing the mean pair-wised distances in the space of inferred 
genotype probabilities. On average, we observe shorter mean pair-wised distance in both 
carriers of risk loci 1 and 2, rather than the overall mean pair-wised distance among all 
sampled individuals. This indicates that true carriers at each risk loci can be identified 
correctly as they have similar inferred genotype probability (see Appendix B for details). 
2.3.2 Power improvement in sib-pairs 
To evaluate the power gain from our algorithm, we simulate datasets of  = 500 cases 
with siblings each, under different parameter settings with 5, 10, or 15 covariates affected 
by one risk variant, and with effect sizes on each covariate ranging from 1.0 to 2.0. We 
analyze the covariate data with CASES and stratify /2 cases with the highest estimated 
probability of carrying the subtype. Using this stratified sample of cases, we perform 
association tests on the risk locus, and calculate the power under significance level 
A = 5 × 10*7 . We compare our testing power to association tests using all   cases 
(figure 2.2). 
When no covariate is affected by the risk variant (covariate OR = 1.0), the power using 
stratified subtype of cases is constantly lower than using all cases, reflecting the loss of 
power due to a reduced sample of half cases. With increasing number of co-inherited 
covariates and increasing covariate OR, the ability to identify cases carrying the 
underlying risk variants is strengthened, thus we observe improved power to detect the 
association when using these stratified cases. Specifically, the power using stratified 
cases is higher than the power using all cases when analyzing 10 affected covariates with 
moderate effect sizes (OR < 1.3) or 5 covariates with greater effect sizes (OR < 1.5). 
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When analyzing 15 covariates strongly affected by the underlying risk variant (OR >
1.8 ), using our stratified cases enriched the power for even more than ten times, 
compared to the baseline power using all cases. 
So far we assume that all covariates analyzed in our model are affected by the risk 
variant. In practice, these informative covariates are unknown and most enrolled 
covariates may be non-informative in identifying subtypes. To evaluate how mixing 
informative and non-informative covariates would affect the performance of CASES, we 
consider scenarios where we analyze up to 50 covariates in our model while only 5 
covariates are affected by the underlying risk variant. We analyze the dataset blind to the 
knowledge about which covariates are affected (figure 2.3). Not surprisingly, the 
difference between using only informative covariates (red dashed line) and using both 
informative and non-informative covariates is decreasing when the effect size on each 
informative covariate increases. However, including non-informative covariates only 
have a small effect on the ability to identify risk variant carriers. Even when only 10 
percent (5 out of 50) covariates in our model are truly informative (black dashed line), the 
power using stratified subtype of cases still outperforms the power using all cases when 
the risk variant affect each of the 5 informative covariates with OR ≥ 1.6. In general, our 
algorithm distinguishes non-heritable factors, such that the testing power is mostly driven 
by covariates truly affected by the heritable risk variants. 
We also evaluate the performance of our algorithm for a range of different effect sizes 
(Appendix C). Most importantly, genetic variants may only affect the observed 
covariates, but not the phenotype (i.e., not true risk variant). Indeed, we want to verify 
that our algorithm does not stratify individuals carrying such variants, which can 
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otherwise increase type I error rate in association studies. We apply our algorithm on 
simulated datasets where the genetic variant has phenotypic OR equals 1.0 to evaluate the 
type I error rate using our stratified samples. We observe an error rate fluctuating around 
the nominal significance level. 
2.3.3 Models with more than one variants affecting the same covariates 
So far we present results based on the assumption that different subtypes are represented 
by different sets of covariates, where each of these mutually exclusive sets of covariates 
is affected by one risk variant. To evaluate if more than one risk variants affecting the 
same set of covariates would affect our algorithm performance, we consider scenarios 
where 10 covariates are affected by risk variant 1, while 0, 5, or 10 out of these 10 
covariates are also affected by another risk variant 2. As in practice, the number of 
subtypes in unknown, we compare two models with K = 1 and K = 2, and evaluate the 
power to detect phenotypic association at variant site 1 for each model (Appendix D). 
In general, we observe increased power to detect the association at variant site 1 under 
both  = 1 and  = 2 models. More importantly, the selection of   results in different 
algorithm performance: The  = 1 model achieves higher power than the  = 2 model 
when 0 or 10 out of the 10 covariates affected by risk variant 1 are also affected by 
variant 2; while  = 2 model outperforms when 5 out of 10 covariates are affected by 
both variants (Appendix D). In practice, specifying the “best” value of  improves the 
efficiency of our algorithm. We suggest a sequential procedure for model selection of  
(Appendix E). 
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2.3.4 Power improvement in unrelated individuals 
To evaluate if CASES provide valid effect size estimates from sib-pair data, we simulate 
multiple scenarios with different true effect sizes and different sample sizes of sib-pairs, 
and compare our estimates from CASES to the true parameters by the mean squared 
errors (MSE) (figure 2.4). In general, our effect size estimates are more accurate when 
the underlying risk variant has stronger effect on a covariate, or when we have larger 
sample sizes of sib-pairs. Specifically, the estimation based on 200 sib-pairs requires the 
covariate strongly affected by the underlying risk variant with OR > 1.8, to achieve the 
same accuracy as the estimation based on 500 sib-pairs when a covariate is only 
moderately affected by the risk variant (OR = 1.2) 
Consequently, our algorithm defines heritable disease subtypes based on these identified 
models of covariates in sib-pairs. To evaluate if these identified indicators (sets of 
covariates) for each subtype can be generalized and applied to other samples of unrelated 
affected individuals from the same target population, we simulate two samples, a model 
simulation sample of sib-pairs and a testing sample of unrelated affected individuals. 
In the first step of this analysis, we apply CASES to the sib-pair dataset to estimate the 
underlying risk variants’ effect sizes on covariates. 
In the second step, given these effect size estimates from sib-pairs, we calculate any 
individual’s probability of subtype membership, in the sample of unrelated affected 
individuals, conditional on the same set of covariates. We then stratify these unrelated 
affected individuals based on their probabilities of subtype membership. 
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To evaluate the benefit using these stratified subsamples of cases, we consider datasets of 
2,000 unrelated affected individuals under the same scenarios as in the sib-pair dataset, 
and stratify these unrelated affected individuals with the top-half estimated probabilities 
of belonging to one subtype. We then compute the power in association studies using this 
stratified sample of cases under genome-wide significance level ( A = 5 × 10*H ), 
compared to the power using all 2,000 cases (figure 2.5) for different effect sizes on 
covariates. Specifically, the power using all cases (dotted line) is constant since it does 
not depend on information provided by covariates. When no covariate is truly affected by 
the risk variant (covariates OR = 1.0), the power of using the stratified sample is smaller 
than the power using all cases due to the reduced sample size. Similar to the power in sib-
pair datasets, testing power using our stratified sample of cases increases with the number 
of covariates, and with effect sizes on covariates. If only 5 covariates are affected by the 
risk variant, using our stratified sample provides higher power than using all cases when 
the variant has moderate (OR ≈ 1.3) effect sizes on these covariates. If we have more 
than 10 covariates affected by the same risk variant, using stratified cases will lead to a 
much higher testing power even if the effect on each covariate is as weak as less than OR 
≤ 1.2. 
2.4 Discussion 
We have presented a novel algorithm to identify heritable subtypes of a complex disease. 
We model clusters of covariates that are co-inherited with the studied phenotype within 
families to define subtypes attributable to one or more underlying risk variants. We are 
thus able to use these estimated subtype memberships select subsamples of affected 
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individuals that are genetically more homogeneous. Focusing on the selected sub-sample 
of cases can increase the power in association tests between the subtype-specific risk loci 
and the phenotype of interests. Furthermore, our algorithm provides estimates about the 
risk variant’s effect sizes on different covariates. Such estimates can be applied to 
calculate the posterior probability of subtype membership in other samples from the same 
target population, given the same set of observed covariates. Indeed, we are able to 
generalize our estimations to unrelated affected individuals, to define genetically more 
homogeneous subtypes of the disease. 
Compared to traditional endophenotype approaches in complex diseases; our algorithm 
has at least four advantages. First, we model variation within and between sib-pairs, thus 
providing evidences that subtypes reflected in covariates are truly heritable. In contrast, 
methods using traditional mixed models (Schulze et al. 2006) and principal component 
studies (Wang et al. 2009) do not distinguish if the resulting subtypes are due to genetic 
or non-genetic factors. 
Second, our algorithm identifies informative subsets from a large set of covariates for 
endophenotypes, before knowing any genotype information. Thus, it is more 
generalizable to any complex disease of interest, and may discover novel regions 
associated with the study phenotype. In comparison, existing methods (Andreassen et al. 
2013; Wen and Lu 2013) require genotypes in a set of previously reported SNPs to select 
co-inherited covariates, while other methods require prior pleiotropic knowledge to 
define subtypes (Morris et al. 2010; Andreassen et al. 2013). 
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Third, our algorithm obtains a quantitative definition of the modeled subtypes. This 
subtype definition can then be applied to other samples of unrelated affected individuals 
from the same target population. We are able to stratify unrelated affected individuals 
based on their subtype membership, to create genetically more homogeneous sample of 
cases. Based on our simulation results, using these sub-samples as cases will increase the 
power to detect associations under a wide range of scenarios. 
Fourth, our method is tolerant to missing data as such data can be imputed in MCMC. 
When an individual has covariates missing at random, the posterior probability of 
subtypes can be inferred from the same mechanism, such that it is equivalent to the 
marginal probability conditional on the remaining covariates. 
Our algorithm is of interests in different studies. First, it identifies individuals carrying 
specific risk variants. It thus can be applied to re-sequencing studies to prioritize affected 
individuals more likely to carry risk variants. Second, it can be applied to association 
studies to select the sample of cases caused by the same risk variants, to increase the 
testing power through increased risk allele frequencies in the case group. When diagnosis 
is based on large sets of clinical measurements and questionnaires, our method fits 
naturally as such measurements can be used directly as observed covariates to define 
endophenotypes to identify different genetic basis. 
In summary, we have developed a general framework for defining endophenotypes and 
selecting genetically homogeneous subsamples of affected individuals. Comparing to 
other approaches, our algorithm is more flexible and can be used to improve the power of 
single marker tests in GWAS studies. It can also be applied to prioritize affected 
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individuals in re-sequencing studies such that affected individuals from the same genetic 
origin of the disease are more likely to be sampled. 
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Table 2.1 Model parameters in CASES. 
Notation Parameters 
 Number of sib-pairs 
 Observed covariates 
 Number of covariates 
 Underlying genotypes at risk loci 
 Number of risk loci (number of subtypes) 
 Vector of risk allele frequencies 
 Matrix of risk allele effect sizes on disease and covariates 
	 Matrix of between covariates effect sizes 
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Figure 2.1 Figure A: Mean rank comparison between carriers and non-carriers when 
using 3, 5, 10, or 15 covariates. The horizontal axis represents effect sizes on covariates 
ranging from 1.0 to 2.0. The vertical axis represents mean rank differences. Figure B: 
Risk allele frequency in stratified cases. The horizontal axis represents stratification sizes, 
from 20 to 200. The vertical axis is the observed risk allele frequency in sampled cases. 
Results are shown for a sample of size 200 and risk allele frequency of 5%, the effect size 
to the disease is 1.5. 
A.                                              B. 
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Figure 2.2 Power comparison in association tests between using full samples (dotted 
horizontal line) and using stratified samples. The horizontal axis represents effect sizes 
on covariates ranging from 1.0 to 2.0. The vertical axis shows testing power under 
significance level A = 5 × 10*7 . The red, green, and black solid curves indicate the 
power using stratified subtypes when 15, 10, and 5 covariates are in our model. 
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Figure 2.3 Power comparison in association tests between using full samples (dotted 
horizontal line) and using stratified samples based on 5 informative covariates. The 
horizontal axis represents effect sizes on covariates ranging from 1.0 to 2.0. The vertical 
axis shows testing power under significance level A = 5 × 10*7. The red, blue, brown, 
green, and black dashed curves indicate the power using stratified subtypes when 0, 5, 10, 
20, and 45 non-informative covariates are analyzed jointly with 5 informative covariates. 
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Figure 2.4 Mean squared error (MSE) comparing the risk variant’s estimated effect sizes 
and the true value. The vertical axis is the mean squared error. The horizontal axis 
represents the increased sample size. The three red curves are the MSE of the effect size 
estimates on covariates, where the true values are 1.2, 1.5, and 1.8. The black curve is the 
effect sizes on phenotype whose true value is also 1.5. The estimated effect on the 
phenotype shows the same accuracy as the estimated effect on covariates when true 
effects are of same level. 
 
  
 34 
 
Figure 2.5 Power curves in external datasets of 2,000 unrelated cases and 2,000 controls. 
The horizontal axis represents effect sizes on covariates ranging from 1.0 to 2.0; and the 
vertical axis shows testing power under genome-wide significance level (A = 5 × 10*H). 
The power using all 2,000 cases is fixed at 0.045 and is represented by the black dashed 
line. The red, green, and black solid lines indicate power curves using stratified samles 
when 15, 10, and 5 covariates are enrolled and affected by the risk variant. 
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Chapter 3 Modeling linkage disequilibrium for population genotype 
data using a coalescent-based method 
3.1 Introduction 
In population genetics, linkage disequilibrium (LD) represents the non-random 
association structure of two or more alleles, at different loci, which descend together 
from the same ancestral chromosomes. Modeling of LD, which approximates the 
evolutionary history of sampled haplotypes, is crucial in many aspects of genetic studies 
such as haplotype reconstruction (Stephens et al. 2001; Stephens and Donnelly 2003), 
genotype imputation (e.g., Howie et al. 2009; Li et al. 2010; Howie et al. 2012), variant 
calling (e.g., Li et al. 2011; Bizon et al. 2014), and mapping of complex trait loci 
(Wellcome Trust Case Control Consortium 2012; Edwards et al. 2013). 
Traditionally, LD is modeled sequentially across the genomic region of interest (ROI). 
For instance, several studies have modeled LD in neighboring SNPs as a Markov process 
when estimating recombination rates and other population genetic parameters (Nielsen 
2000; Fearnhead and Donnelly 2001). More recently, Li and Stephens (2003) have 
proposed a hidden Markov model (HMM) to approximate LD across different loci. Such 
HMM algorithm has been proved an efficient approach, and is widely implemented in 
many existing software packages for genetic studies to model LD of sampled haplotypes, 
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such as PHASE (Stephens et al. 2001; Stephens and Donnelly 2003), BEAGLE 
(Browning and Yu 2009), MaCH (Li et al. 2010) or THUNDER (Li et al. 2011). 
However, the HMM algorithm oversimplifies the variation of mutation and 
recombination rates across ROI – especially if the ROI is highly polymorphic and/or has 
high recombination rates, or if sampled individuals are from an admixed population. 
Potentially, this over-simplification can be reduced by implementing larger reference 
panels from the same or similar target populations as a larger “pool of haplotypes,” to 
achieve higher accuracy in reconstructing sampled haplotypes (Huang et al. 2009; Huang 
et al. 2011).  Most studies performed to date have selected reference panels from external 
databases such as the International HapMap Project (The International HapMap 
Consortium 2005; Frazer et al. 2007) or the 1000 Genomes Project (The 1000 Genomes 
Project Consortium 2010). Following this path, several studies have also proposed other 
strategies to select more efficient reference panels (e.g., Jewett et al. 2009; Pasaniuc et al. 
2010; Liu et al. 2013) through local ancestry inferences (e.g., RFMix; Maples et al. 2013) 
to improve the HMM-based model of LD. Unfortunately, HMM algorithms still face 
challenges in modeling LD in certain complex genomic regions lacking efficient 
reference panels, such as HLA genes in the human MHC region (Cao et al. 2013). 
As an alternative approach, when no efficient reference panel is available, several studies 
have proposed coalescent-based methods to improve the modeling of LD through the 
inferred ancestral recombination graph (ARG; Nordborg 2000; Nordborg and Tavare 
2002). At each position across the ROI, these methods estimate the genealogy of sampled 
haplotypes by analyzing the genotype similarity at surrounding variant sites. LD is then 
modeled through shared and non-shared genealogies between different loci. Because 
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genealogies are analyzed in parallel position-by-position, these coalescent-based methods 
allow more variation in LD across the ROI, compared to HMM algorithms. 
Although promising, the coalescent-based model of LD is only fulfilled in a few studies 
under specific assumptions, due to its computational complexity. For instance, Burkett et 
al. (2013b) proposed a computational tool based on Zӧllner and Pritchard (2005) to make 
inferences about genealogies using unphased genotype data, and compared the accuracy 
between their inferences to the haplotypes estimated by HMM algorithms to evaluate 
their model. However, their method assumes the same first-order Markov process as in 
Zӧllner and Pritchard (2005), which ignores the LD between more distant loci to simplify 
its computation. Therefore, these methods are not applicable in studies using dense SNP 
data or using sequencing data. 
In the present study, we implement an HMM-enhanced algorithm to coalescent-based 
modeling of LD, which combines the local LD information from shared genealogies with 
the more distant LD approximated by the HMM algorithm. Based on this more careful 
modeling, we are able to apply this coalescent-based algorithm to estimate LD using 
densely genotyped or sequenced data. 
To evaluate the accuracy of our model, we focus on two applications highly related to the 
LD modeling: reconstructing haplotypes and mapping of complex trait loci. In simulation 
studies, we compare our results in these two applications to results using traditional 
HMM-based algorithms, to determine whether our new model improves the 
understanding of sampled haplotypes. 
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3.1.1 Haplotype reconstruction 
Traditionally, HMM-based algorithms have reconstructed haplotypes through an MCMC, 
by approximating each haplotype as a mosaic of short segments imperfectly copied from 
one or more ancestors in the target population. Without any local ancestry information, 
traditional HMM algorithms (e.g., PHASE; Stephens et al. 2001; Stephens and Donnelly 
2003) assume uniform prior probability of being copied from any specific ancestor 
haplotype.  
As an alternative in the present study, we apply more informative prior probability of 
ancestries for each haplotype segment conditional on the inferred genealogy through our 
modeling of LD. Thus, we are able to update the inferred haplotypes more efficiently.  
We set up simulation studies across a wide range of population genetic models to 
evaluate our method. Specifically, we reconstruct haplotypes from these simulated 
diploid samples through our inferred genealogies, and compare them to the true 
haplotypes to calculate the miscalling rate of the inferred haplotypes provided by our 
algorithm. We then compare our results to the miscalling rate of inferred haplotypes 
using HMM algorithms (MaCH; Li et al. 2010) to evaluate if our model of LD extracts 
more information about the construction of sampled haplotypes. 
According to our simulation results, our algorithm provides comparable haplotyping 
accuracy with MaCH in sequenced regions under neutral recombination rates. In 
sequenced regions where the recombination rate is more than 10 times higher than the 
neutral rates, the inferred haplotypes based on our model of LD are more accurate than 
the haplotypes inferred by MaCH. 
 39 
 
3.1.2 Mapping of complex trait loci 
Traditionally, fine mapping is applied subsequent to genome-wide association studies 
(GWAS), to identify candidate regions harboring disease-causing mutations. Focusing on 
a set of GWAS-selected loci with detected phenotypic associations, fine mapping 
algorithms calculate the Bayes factor in favor of associations at each variant site, to 
calculate the posterior probability of causality for fine mapping (Servin and Stephens 
2007; Stephens and Balding 2009). Typically, these methods require that functional loci 
to be sought must be included in the GWAS-selected set. 
Alternatively in the present study, we make inferences about genealogies based on our 
model of LD. Conditional on these estimated genealogies, we then identify candidate 
regions harboring causal mutations by evaluating the distribution of cases and controls on 
the ARG across ROI (figure 3.1). Instead of focusing on certain GWAS-selected 
candidate regions, we analyze the entire ROI directly for causal loci. 
To evaluate our algorithm, we simulate samples of several hundred cases and controls 
from the target population. Under different simulated scenarios, we compare our mapping 
results to the results provided by traditional fine-mapping approaches based on single 
marker association tests (BIMBAM; Servin and Stephens 2007). 
According to our simulation results, our algorithm correctly localizes sub-regions 
harboring causal mutations under scenarios where single marker tests have low power to 
detect any association signal. Moreover, since we make inferences about genealogies 
through jointly analyzing genotypes at multiple sites, our algorithm performs robustly 
when the genotype at the causal site is missing. 
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3.2 Methods 
3.2.1 Estimating genealogies 
Suppose we have a sample of   individuals, each sequenced in a region of K  Mbs 
containing  variant sites. We let  denote the genotypes of the 2 diploids in  variant 
sites, where 8 = [L, … L/] is the physical positions (in base pairs) from each variant 
site to the left end of the sequenced ROI. We denote MN as the sample genealogy at a 
position O  base pairs to the left end of the target ROI, which contains the ancestral 
relationship topology, time to each coalescent event, as well as the length of each 
sampled haplotype sharing the same local genealogy with position O. 
At each position, we make inferences about the posterior genealogy probability, MN|, 
conditional on the observed genotypes at all  variant sites. We approximate this posterior 
distribution MN| by an MCMC sampling method similar to Zӧllner and Pritchard 
(2005). 
To begin, we assume known haplotypes P = [ℎ, … ℎ2R] from genotypes  in  diploids 
and let ℎ
  denotes haplotype ’s allele type at variant site . To make inferences about 
MN|P, we treat these haplotypes as the external nodes of a coalescent tree. We then let 
PS = [ℎ2RT, … ℎ7R*] denote the unknown haplotypes of the 2 − 1 common ancestors 
(treated as internal nodes) of the genealogy, where ℎ7R* is the haplotype of all sampled 
individuals’ most recent common ancestor (MRCA). 
Without loss of generality, we assume the position O locates at the left end of the ROI 
(O = 0), such that each variant site  is located L based pairs to the right of position O. 
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In practice, for variant sites locate to the left of O, a similar algorithm can be applied 
easily as a mirror image. As in Zӧllner and Pritchard (2005), we denote the 
recombination rate and mutation rate as V/2 and W/2. We let X = [Y, … Y/] denote the 
physical distances between two consecutive variant sites, such that Y = L  and Y =
L − L* for site  = 2, … . Moreover, we denote Z as the vector of coalescent times in 
all 2 − 1 coalescent event on MN (Table 3.1). 
Moreover, we denote [
 as the variant site closest to O at haplotype  that is not inherited 
from parental node on MN  (due to recombination). We then use  = [, … 7R*]  to 
denote the lengths of haplotypes descending together with position O in genealogy MN , 
such that all 
 =   for all observed haplotypes (external nodes)  = 1, … 2 . For any 
internal node  with left and right descendant nodes K and \, ] = L^O[_, [` . 
Then the posterior probability of genealogy, conditional on the sampled haplotypes, is 
proportional to the total likelihood: 
MN|P = a, Z, P′, \, V, c|P ∝ P, PS|\, V, c, a\|V, c, aVca 
Similar to Zӧllner and Pritchard (2005), we apply uniform prior probabilities on V, c, and 
a. Given these population genetic parameters, we propose possible recombination events 
in the MCMC using a Metropolis-Hasting algorithm to approximate \|V, c, a. For the 
joint haplotype probability P, PS|\, V, c, a, we re-write it as a series of conditional 
probabilities of haplotypes: 
P, PS|\, V, c, a = ℎ7R*|\, V, c, a ∙ … ∙ ℎ|ℎ2, … , ℎ7R*, \, V, c, a 
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For each conditional probability term, we split this haplotype probability into two parts as 
follows: For any node d with parental node , we define ℎ
Ref  as the segment of all ℎ
f 
with  < [f, which is inherited from ℎ
g. We also define ℎhijf  as the segment of all ℎ
f with 
[f ≤  ≤ f, which is copied from other haplotypes due to recombination (figure 3.2). 
Consequently, we model the conditional probability of ℎf as follows: 
 ℎf|ℎfT, … , ℎ7R*, \, V, c, a = =ℎ
Ref >ℎg, c? ∙ =ℎhijf >ℎfT, … , ℎ7R*, \, V, c, a? 
The probability for inherited segment ℎ
Ref  can then be modeled through mutation 
models. We then consider the recombined segment, ℎhijf , as a mosaic of imperfect copies 
from a “pool of haplotypes” in the target population, and model this segment through an 
HMM model (Li and Stephens 2003). 
We use an MCMC to draw a large number (8) of possible coalescent trees MN9 (L =
1, … 8), to approximate the posterior probability of genealogy MN|P, conditional on 
the sampled haplotypes. 
3.2.2 Haplotype reconstruction 
In practice, genotyping and sequencing technologies provide diploid genotypes at each 
variant site, but do not provide haplotype information. Given genotypes , we propose a 
method to make inference about haplotypes P through our estimation of genealogies. 
Let P be the initial state of estimated haplotypes conditional on . During our MCMC, 
we begin with P to make inferences about genealogies at each position O. Suppose 
MN  is the initial draw of possible genealogy conditional on P , we then propose 
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possible updates of haplotypes P in accordance with , to the MCMC: We let ℎf 
and ℎf2 denote the two haplotypes of individual d in P, where ℎ
Ref and ℎ
Ref2 are 
the inherited haplotype segments from parental node 1 and 2 in estimated genealogy 
MN . We then randomly choose a variant site  < min [f, [f2  where the two 
haplotypes are ambiguous in individual d, and propose a switch of alleles at ℎ
f and ℎ
f2 
based on a Metropolis-Hasting algorithm to update the haplotypes. We update these 
haplotypes within the Markov chain that makes inferences about genealogies, such that 
the marginal probability of haplotypes in short segments surrounding O, PN|, can 
also be approximated by the random draws from the MCMC. We sum over these random 
draws from PN|  at each analyzed position O , and map the draws at different 
positions as a mosaic to reconstruct the entire haplotype within ROI. 
3.2.3 Mapping of complex trait loci 
Traditionally, fine mapping is applied to an initial set of candidate loci reported by 
association studies, which is based on the assumption that at least one causal variant must 
be carried by this initial set of loci with reported phenotypic association. As an 
alternative, we propose an algorithm mapping causal variants through our estimated 
genealogies across the entire ROI, which is not based on this assumption. 
We consider a study with  cases and  controls, each sequenced in an ROI of K Mbs. 
We let n  denote the observed phenotypes, where o
 = 1 if individual   is an affected 
individual (case), and o
 = 0 if otherwise. We assume there is one causal variant within 
this ROI, and let p denote the indicator of the causal variant, such that p = O represents 
that a causal mutation is carried at the position O base pairs to the left end of the ROI. We 
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then make inferences about the genealogies of cases and controls at each position O, to 
map candidate regions harboring disease causal variants. 
Theoretically, we could make inferences about the sample genealogy MN at all K positions 
within the ROI. However, this is unnecessary since positions extremely close to each 
other are highly likely to share the same genealogy. Moreover, we are not able to 
distinguish the genealogies between two closely located positions, where no variant site 
is observed and genotyped in between. Instead, we borrow the idea of “focal points” 
suggested by Zӧllner and Pritchard (2005) as the set of positions where we make 
genealogy inferences. Specifically, we estimate the genealogy at one position in every 
short genomic segment of 10Kbs. 
At each focal point O , our goal is to calculate the posterior probability of causality 
p = O|n, . By Bayes rule, this is proportional to: 
p = O|n,  ∝ n, |p = Op = O. 
The analyzed positions, the “focal points”, are uniformly selected in every 10Kbs. 
Therefore, we assume they are equally likely to be harboring the causal mutation, and 
apply uniform prior probability of causality p = O to each focal point O. We then 
calculate the joint probability of phenotypes and genotypes, n, |p = O, similar to 
Zӧllner and Pritchard (2005): 
n, |p = O = q n|MN, p = OMN|YMN 
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We approximate MN|, the posterior probability of genealogies given genotypes, by 
sampling possible genealogies from our MCMC described above. We then approximate 
the probability above by: 
n, |p = O = 18 < n|MN
9, p = Or
9s
 
We assume a multiplicative model, and denote  and  as the phenotype penetrance 
level on any individual carrying homozygous wild type alleles and variant type alleles. 
Therefore, the joint probability of phenotypes and genotypes is equivalent to: 
(n)MN9, p = O+ = t (n)MN9, , +guvgw
YY 
We then evaluate n|MN9, ,  by integrating over possible mutations on any branch 
of the tree MN9 as Zӧllner and Pritchard (2005). 
In the end, we apply Monte Carlo integration over all focal points O, to estimate the 
posterior probability of causality p = O|n,  at each position, and build a credible 
region to fine map candidate loci harboring causal variants. 
3.2.4 Algorithm evaluation 
To evaluate our algorithm performance in haplotype reconstruction, we simulate datasets 
containing 400 haplotypes using a coalescent haplotype simulator (Hudson 2002). Each 
haplotype is sequenced in a 1Mbs with 500Kbs flanking spaces on both ends. All 
singletons are removed from the data since these single observations provide no 
information of LD. We apply neutral mutation rate, and consider different recombination 
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rates ranging from 1 × 10*H to 2 × 10*x. We then randomly assign these haplotypes into 
200 diploid individuals. We mask the haplotype information, and apply the diploid 
genotypes into our algorithm to make inferences about the sample genealogies. 
We then apply both our method and a HMM algorithm (MaCH; Li et al. 2010) to these 
genotype data, and compare the consequent estimated most likely haplotypes to the true 
haplotypes using both algorithms. For each simulated scenario, we categorize variant 
sites into 4 bins minor allele frequency levels: less than 1%, from 1% to 5 %, from 5% to 
20%, and greater than 20%. We compare our reconstructed haplotypes to the true 
haplotypes in each simulated dataset, and calculate the ratio of the number of alleles 
mislabeled into the opposite haplotype over the total number of heterozygous sites as the 
miscalling rate. We calculate this miscalling rate of our haplotype estimation within each 
category, and compare it to the same rate calculated from haplotype reconstruction using 
MaCH, to evaluate if our algorithm reconstructs haplotypes more accurately. 
To evaluate our algorithm performance in mapping of complex trait loci, we simulate a 
dataset of 2:  of haplotypes, and randomly assign these haplotypes into :  diploid 
individuals. Each individual is sequenced in a 1Mbs ROI with 500Kbs flanking region on 
both ends. We then randomly pick one variant site within ROI as the causal variant under 
different minor allele frequency (MAF) levels. We consider 3 MAF levels with different 
risk allele frequency levels, 1%, 5%, or 20%, to evaluate our algorithm performance. We 
then assign a phenotype to each individual conditional on his genotype at this causal site 
under a multiplicative model. The risk allele effect size is OR = 2.0 for the rare risk 
allele with MAF = 1%. We set OR = 1.5 for risk allele with MAF = 5%, and OR =1.2 
for the common risk allele with MAF = 20%. Under each scenario, we randomly sample 
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400 cases and 400 controls, and apply these sampled individuals into our algorithm to 
make inferences about genealogies. Conditional on the estimated genealogy, we calculate 
the posterior probability of causality across the ROI, and construct 90% Bayesian 
credible regions based on the top ranked focal points to evaluate the mapping accuracy 
using our algorithm. Under each scenario, we simulate 5 datasets, and calculate the 
median width of our credible regions, as well as the distance between causal site and the 
position with greatest posterior probability of causality, to evaluate our mapping 
accuracy. We also calculate the coverage probability to determine if the credible region 
provided by our algorithm correctly locates causal sites. 
To evaluate if our algorithm provide comparable results regardless of the causal site is 
genotyped or not, we mask the genotype at causal site in each simulated dataset, and re-
apply our method to calculate the same statistics for fine mappings. We compare our 
results with and without genotypes at causal sites, to evaluate our algorithm robustness. 
3.3 Results 
3.3.1 Reconstructing haplotypes 
To evaluate if our algorithm improves the accuracy in haplotype reconstruction, we 
simulate multiple datasets under different recombination rates, ranging from a neutral rate 
of 1 × 10*H  to as high as twenty times of the neutral level (2 × 10*x ). Under each 
recombination level, we simulate datasets each containing 200 diploid individuals 
sequenced in an ROI of 1Mbs. We also include 500Kbs flanking regions on both sides of 
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the ROI. We then categorize the variant sites within ROI into 4 MAF levels: smaller than 
1%, from 1% to 5%, from 5% to 20%, and greater than 20% (figure 3.3). 
We then compare the most likely haplotype estimates using our method to the true 
simulated haplotypes. Under each MAF level, we calculate the rate of miscalled variant 
sites over the total number of heterozygous sites within our sample provided by our 
algorithm, and compare it to the same miscalling rate provided by MaCH (Li et al. 2010). 
Using both our method and MaCH, we observe that haplotype reconstruction is more 
accurate with lower recombination rates, using both our method and using MaCH. This is 
reasonable since higher rates result in more recombination events along the genomic 
region, cutting the ROI into much smaller segments where each segment contains less LD 
information to the neighboring loci. When recombination rate is less than 2 × 10*H 
(black and green lines), both our method and MaCH provide comparable accuracy where 
less than 2 percent heterozygous alleles are mislabeled in the inferred haplotypes. Under 
low recombination rates, we also observe lowest haplotyping accuracy in rare allele sites 
with MAF less than 1%. Specifically, using our method slightly improves the accuracy in 
these sites where variant alleles are only observed a few times in our sample. 
When the recombination rate is 5 to 20 times higher, both methods experience reduced 
accuracy. Using MaCH, almost 18 percent of all heterozygous alleles are mislabeled into 
the opposite inferred haplotype when the recombination rate is 2 × 10*x (red solid line). 
In contrast, using our coalescent-based algorithm correctly identifies around 1/5 of these 
mislabeled sites, and reduces the overall miscalling rate to 14 percent across all variant 
sites (red dashed line). Moreover, such improvement is strongest in rare allele sites (MAF 
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< 1%), where miscalling rate is reduced by 1/3, and is below 10 percent in these variant 
sites where variant alleles are only observed 2 to 4 times in our sample. 
3.3.2 Mapping complex trait loci 
To evaluate if our algorithm can be applied to fine mapping for candidate region 
harboring disease causal variants, we simulate datasets with 400 cases and 400 controls 
under different risk allele models. We consider rare to common risk alleles with different 
effect sizes as described in the methods section. 
For a small sample of a few hundred individuals, traditional single marker tests are not 
sufficiently powered to detect the phenotypic association from either rare variants with 
MAF less than 1% or common variants with moderate to weak effect sizes (OR less than 
1.2). To begin with, we illustrate a single realizations from our simulated datasets, for 
such low-powered results in single marker tests when the risk variant is rare with 1% 
MAF and disease effect size 2.0 (figure 3.5). We apply both Fisher’s exact test (PLINK; 
Purcell et al. 2007) and Bayesian approaches (BIMBAM; Servin and Stephens 2007) to 
detect single marker associations, and compare the consequent p-values (figure 3.5A, 
black dots) and posterior probability of associations (PPA; figure 3.5B, grey dots). Both 
methods provide similar results that we observe no signal associated to the disease. 
When association studies have low power, loci harboring causal variants are hardly 
reported as candidate regions with phenotypic associations. If so, traditional fine mapping 
approaches are rarely performed since no signal has been found in the target region, and 
are not applicable to localize sub-regions for causal variants; In contrast, our algorithm of 
fine mapping does not depend on the power of single marker association tests. 
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Specifically, we apply our algorithm to make inferences about genealogies at different 
positions across ROI. Based on the estimated genealogies at a set of focal points across 
ROI, we then calculate each focal point’s posterior probability of carrying causal variants 
(figure 3.5B, red dotted line), and construct 90% credible regions to localize causal loci 
(figure 3.5B, red underlines). According to our result, the posterior probability of 
causality increases when moving towards the causal position, and peaks at focal points 
less than 20Kbs from the exact site carrying the disease risk variant. Moreover, based on 
our credible interval, we correctly localize the causal variant site in two sub-regions 
covering a region less than 350Kbs in the ROI. Compared to traditional mapping 
approaches, our algorithm successfully identifies cumulative weak signals around the 
causal region, and down-weights other noise signals from more distant loci, to correctly 
localize sub-regions harboring disease causal variant. 
To evaluate our algorithm performance in mapping candidate regions harboring causal 
variants, we simulate 5 datasets for each considered risk variant type. Under each 
scenario, we calculate the median distance between the causal site and the focal point 
with the strongest estimated posterior probability of causality (round-up in 5Kbs, as the 
mid-points in two consecutive focal points in our analysis). Under this small sample size, 
the accuracy of our fine mapping algorithm is affected by the frequency of risk alleles 
observed in the study sample. On the one hand, when the causal variants are common, 
our estimated most likely position harboring these causal variants is on average less than 
15 to 20Kbs from the exact position of the causal variant. On the other hand, when causal 
variants are rare (MAF < 1%), our estimated most likely positions is on average 30Kbs 
from the causal site. Across these scenarios, the estimated most likely position is 
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consistently within 2 to 3 focal points from the exact position – given that we only make 
inferences at focal points in every 10Kbs in present study. 
Furthermore, we construct the 90% credible region for each realization, and summarize 
the median credible region width per scenario (table 3.2) to evaluate our algorithm 
performance. We observe similar trend as in point estimates of most likely positions that 
the accuracy of fine mapping is determined by the frequency of risk alleles observed in 
study sample. When we are mapping rare risk variants with MAF less than 1%, our 
method suggests a region covering over 350Kbs across the ROI. Our credible region 
width decreases by half when the risk allele frequency is around 5%, and further reduces 
to less than 140Kbs when the risk allele frequency is 20% (even when a diseased effect 
size to the disease). 
To evaluate if our algorithm provides robust mapping accuracy when the causal variant is 
not genotyped in sampled data, we mask the genotype at the true position in our sample 
of sequenced individuals. We then re-apply our algorithm to make inferences about the 
genealogy, and to mapping candidate regions covering causal variant site. Compared to 
previous results when the causal variant is genotyped, we obtain comparable mapping 
accuracy with credible interval widths (table 3.2) slightly increased by only a few focal 
points. In general, our results suggest that our fine mapping accuracy is robust to the 
missing genotypes at the exact causal site. 
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3.4 Discussion 
We have presented a novel algorithm to model LD through estimating sample 
genealogies across ROI. At each position, we make inferences about the genealogy at one 
position at a time, based on the genotype similarities at surrounding variant sites co-
inherited with this position. We model the LD between more distant sites using an HMM 
algorithm through estimated mutation and recombination models. By evaluating the 
genealogy at every short segment, we are then able to improve the haplotype 
reconstruction by treating the entire haplotype within an ROI as a mosaic of these co-
inherited short segments. Moreover, by evaluating the distribution of cases and controls 
at genealogies in different positions across an ROI, we are also able to identify candidate 
regions harboring disease risk variants in case-control studies. 
Compared to existing methods, our algorithm has at least three advantages. First, we 
make genealogy inferences at every position independently, such that we allow more 
variations in population genetic parameters such as mutation rates and recombination 
rates across different positions. In contrast, traditional HMM-based modeling of LD (Li 
and Stephens 2003) may over simplify the distribution of these parameters across the 
ROI by assuming certain prior probabilities, thus may experience challenges in studying 
highly polymorphic genomic regions with high recombination rates. 
Second, our algorithm models both local LD and LD between more distant loci carefully: 
We combine the local LD through estimated genealogies with the distant LD modeling 
through a HMM algorithm. Thus our algorithm is applicable to studies using genotype 
data with dense SNPs and studies using sequencing data. In comparison, many existing 
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coalescent-based approaches (Zӧllner and Pritchard 2005; Burkett et al. 2013b) simplify 
the distant LD by assuming first-degree Markov models, which is only appropriate when 
SNPs are sparsely selected across the ROI. 
Third, our algorithm makes inferences about genealogies based on unphased genotype 
data. Our genealogy estimation is then not dependent to pre-phasing quality. This is 
especially beneficial for fine mapping of complex traits loci through estimated 
genealogies, where some traditional mapping approaches are highly sensitive to pre-
phasing accuracy (Morris et al. 2004; Burkett et al. 2013a). Moreover, allowing 
genealogy inferences based on unphased genotype data also improves the haplotype 
reconstruction in regions where traditional phasing algorithms provide less accurate 
reconstructed haplotypes – since each short haplotype segment co-inherited along the 
genealogy provides more local LD information about which alleles are descend from the 
same ancestor. 
Our LD modeling is of interest in different types of genetic studies. First, it contributes to 
fine mapping studies to identify disease causal loci. When practitioners have small 
sample sizes, our algorithm can be especially beneficial in localizing regions harboring 
rare causal variant or common variants with weak effect sizes – where traditional 
algorithms based on single marker tests are not sufficiently powered. According to our 
study, fine mapping based on our genealogy inferences correctly identifies credible 
regions covering causal sites under multiple disease genetic architectures, and 
outperforms traditional algorithm when the risk variant to be sought is rare in study 
sample. Second, it improves the accuracy of haplotype reconstruction through more 
accurately modeled genealogies. It thus can be applied to studies analyzing highly 
 54 
 
polymorphic regions with high gene-densities where traditional approaches experience 
challenges in correctly identifying haplotype information. 
Future implementations of the present study include that one may improve the accuracy 
in identifying recombination hotspots, as well as improve the accuracy in identifying de 
novo rare variants in sequencing studies, through our more careful model of LD based on 
estimated genealogies. Moreover, in the present study, we only select one focal point per 
10Kbs to make genealogy inferences, and apply uniform prior probability of causality at 
every focal point across the ROI. Potentially, higher resolution of focal points can be 
applied to improve the power in estimating genealogies if computational time allows. 
Likewise, more informative priors based on gene densities and variant and more adaptive 
selection of focal points may also improve our mapping accuracy through up-weighting 
positions near causal sites. Furthermore, we evaluate our algorithm performance under 
scenarios where traditional single marker tests have limited power. For instance, in 
testing for rare variants, one may consider using collapsing methods (Burden tests, Li and 
Leal 2008) to jointly analyze multiple rare variants instead of applying single marker 
tests. In future studies, we will make further comparisons to these strategies, to evaluate 
under what conditions our coalescent-based algorithm is preferable.  
In summary, we have developed a general framework to model linkage disequilibrium 
through estimated genealogy. Compared to existing approaches, our algorithm combines 
the advantages in HMM algorithms and coalescent-based algorithms, and allows more 
variation in population genetic parameters. It then improves the accuracy in haplotype 
reconstruction, and enables using unphased genotype data for fine mapping of complex 
trait loci. We also project future applications such as identifying recombination hotspots 
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and calling de novo rare variants in sequencing studies, through this genealogy-based 
modeling of LD.  
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Table 3.1 Model parameters in estimating genealogies at position O. 
Notation Parameters 
ℎ
 Haplotype ’s allele type at variant site  
P Haplotypes of all 2 observed haplotypes 
P′ Haplotypes of 2-1 ancient haplotypes 

 Length of haplotype  restored in MN 
 Vector of haplotype lengths 
[
 SNP closest to O not inherited to haplotype  
\ Vector of not inherited SNP boundaries 
L Distance of variant site  to the left end of ROI 
8 Vector of physical distances to the left end of ROI 
Y Distance of between variant site  and  − 1 
X Vector of physical distances between SNPs 
V/2 Recombination rate 
c/2 Mutation rate 
Z Vector of coalescent times 
a Tree topology of MN 
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Table 3.2 Mapping of complex trait loci using our algorithm through estimated 
genealogies using 400 cases and 400 controls. 
MAF OR Distance 
CI width 
w. causal o. causal 
1% 2.0 30 350 370 
5% 1.5 20 180 190 
20% 1.2 15 140 150 
Distance: between positions with strongest signals to causal variant sites in Kbs. 
CI width: median 90% credible region width in 5 realizations in Kbs. 
w. causal: when causal variant is directly genotyped in study sample 
o. causal: when causal variant site is missing in genotyped data. 
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Figure 3.1 Intuition of mapping of complex traits through genealogy. Figure A: position 
extremely close to causal site with no recombination in between, sharing identical 
genealogy. Figure B: position slightly distant from causal site where one recombination 
occurred, slightly different genealogy. Figure C: position far from causal site where 
multiple recombination occurred, genealogy of phenotypes. 
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Figure 3.2 Illustration of estimated genealogy at the left end of a sample of 6 haplotypes. 
Each sampled haplotype (external nodes) contains 9 SNPs, while the inferred ancestor 
haplotype (internal nodes) lengths differ due to recombination events. For each external 
and internal node, the segment colored in green indicates it is inherited from the parental 
node, while the segment in red means it is copied from other ancestors due to 
recombination. 
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Figure 3.3 Distribution of variant sites in different MAF levels (binned by 4 categories: 
<1%, <5%, <20%, and <50%) across 5 simulated recombination rate levels. 
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Figure 3.4 Miscalling rate in haplotype reconstruction under different simulated 
recombination rates, the solid lines represent miscalling rate using HMM based 
approaches (MaCH), and the dashed lines are miscalling rate through our inferred 
genealogies (Tree). The horizontal axis represents the 4 levels of MAF categories (<1%, 
<5%, <20%, and <50%). 
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Figure 3.5 Results in identifying risk variants. The green line represents the true causal 
position. Black dots in figure A represent p-values using Fisher’s exact tests. In figure B 
D, grey dots represent posterior probability of association. The red dashed lines are 
posterior probabilities provided by our coalescent-based algorithm, while the red and blue 
underlines are the 90% credible regions provided by our algorithm and traditional single 
marker test based fine mappings. 
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Chapter 4 A coalescent-based model using sequencing data in large-
scale association mapping and fine mapping 
4.1 Introduction 
In recent years, GWAS have identified over 1,500 genomic regions associated with 
hundreds of phenotypes (the Catalog of Published Genome-Wide Association Studies, 
http://www.genome.gov/gwasstudies). Thousands of SNPs have been found associated 
with various complex diseases. However, approximately 88% of the variants found in 
GWAS are located in regions that lack obvious functional consequences. Such ambiguity 
leads to unclear conclusions about how these variants affect gene expression and/or the 
regulation of gene expression (Edwards et al. 2013). This uncertainty is in fact not 
surprising, since most GWAS tag-SNPs are not selected for having likely functional 
consequences. Rather, the interpretation of a typical GWAS result is based on the 
assumption that the phenotypic associations detected at tag-SNPs are due to high LD (in 
short physical distance) between these SNPs and the non-genotyped causal variant site. 
Indeed, a successful GWAS study only suggests an initial set of candidate loci marked by 
tag-SNPs with detected associations. A consequent fine mapping study can then be 
performed to make causal inferences about this initial set, to identify one or more loci 
harboring functional variants. 
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Traditionally, existing fine mapping algorithms are based on results from GWAS studies, 
which only analyze a set of GWAS-selected candidate loci with detected phenotypic 
associations (Stephens and Balding 2009; Edwards et al. 2013). To ensure valid causal 
inferences, these GWAS-based fine mapping approaches require that the causal variant 
site must be included in the initial set of candidate regions reported by GWAS. 
With the advances in next generation sequencing technologies, the risk that no causal site 
is reported in the initial candidate set can be reduced by substituting traditional GWAS by 
whole-genome or whole-exome sequencing studies – where each variant site, including 
causal sites, will be directly tested for association. However, causal sites are not always 
genotyped even using sequencing data; they can be filtered due to low quality in low 
coverage sequencing, or the causal variant can be not a SNP but an indel or a CNV. 
Moreover, due to the high cost of sequencing technology, imputation-based approaches 
have been proved efficient to detect rare to low-frequent variant associations (Servin and 
Stephens 2007; Guan and Stephens 2008; Li et al. 2010), yet some rare causal variants 
may still be incorrectly imputed if not observed in the reference panel. After all, 
traditional fine mapping based on single marker association tests still faces the challenge 
that the causal site may remain unidentified. 
Alternatively, several studies have focused on mapping causal variants through the 
estimated genealogies (e.g., Morris et al. 2002; Zӧllner and Pritchard 2005; Tachmazidou 
et al. 2007; Burkett et al. 2013). For a genomic ROI undergoing recombination, different 
positions have different ancestries. Therefore, by evaluating the distribution of cases and 
controls on the genealogies across different positions, we are able to identify positions 
where cases are separating from controls on the ancestry, to locate candidate regions 
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likely to be harboring causal variants. Compared to traditional fine mapping algorithms, 
these coalescent-based approaches directly analyze sampled genotypes across the ROI, 
and thus do not rely on the power in single marker association tests. Moreover, the 
genealogy at each position is inferred through jointly analyzing genotypes at surrounding 
regions. Indeed, these approaches are also more robust to scenarios when causal loci are 
not genotyped – since the missing information in a few non-genotyped variant sites can 
be minimized by the shared genealogies at neighboring positions. 
Unfortunately, existing coalescent-based approaches are computationally intensive. 
Typically, they require MCMC to approximate the posterior distribution of possible 
genealogies conditional on sampled genotypes. With the increased sample size, the 
sample space of possible genealogies grows even faster than exponentially and thus 
creates unfeasible computational intensity in large-scale studies. Therefore, existing 
coalescent-based approaches tend to oversimplify the modeling of LD in haplotypes and 
are restricted to samples of no more than a few hundred individuals. 
In the present study, we propose a framework which utilizes a clustering algorithm to 
reduce the sample space in genealogy inferences, which then enables fine-scale mapping 
of complex trait loci through estimated genealogies applicable to large scaled studies. 
Intuitively, this method is motivated by the observation that sampled haplotypes tend to 
coalesce into a number of common ancestors in a very short period of time, compared to 
the entire coalescent process (Scheet and Stephens 2006). Therefore, if the causal 
mutation occurred at a time far prior to the formation of these common ancestors, we can 
then treat the sub-genealogy under each common ancestor as a cluster, and ignore these 
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lower-end coalescent patterns within each cluster. Consequently, we only need to make 
inferences about the upper-end genealogy of clusters, such that the sample space of 
genealogies is reduced from a function of 2  haplotypes to a function of   clusters 
(figure 4.1). We make inferences about the  clusters similar to the clustering algorithm 
suggested by Scheet and Stephens (fastPHASE; 2006). Given these clusters, we then use 
the same HMM-enhanced model, introduced in Chapter 3, to estimate the genealogies of 
clusters at each position across the ROI. We implement the estimation of genealogies of 
clusters into our own computational package, fastTREE. 
Conditional on the estimated genealogy at any position O within the ROI, we propose a 
Bayesian approach to calculate the posterior probability of association at O, to detect the 
association between genotypes at this position and the study phenotypes. We also design 
a fine mapping approach similar to our method in Chapter 3, which makes causal 
inferences for fine mapping through estimated genealogies across different positions in 
the ROI, to identify candidate regions harboring disease-causal variants. 
To evaluate the performance of our method, we simulate case-control samples using a 
coalescent haplotype simulator (Hudson 2002). We consider sample sizes up to tens of 
thousands of individuals, each sequenced for a ROI in a few Mbs. We also consider 
multiple disease models with different risk allele frequencies and different effect sizes. 
We then compare the mapping accuracy of  our method to the accuracy of traditional 
single marker association tests and subsequent fine-scale mapping (Purcell et al. 2007; 
Servin and Stephens 2007). To evaluate our method’s robustness to the non-genotyped 
causal variants, we mask the true variant site and re-apply our method. We then evaluate 
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if our method provides mapping accuracy comparable to scenarios when the causal site is 
genotyped and analyzed. 
When genotypes at the causal variant site are available in the study sample, both our 
method and traditional approaches based on single marker tests correctly identify 
candidate regions covering these causal sites. Specifically, credible regions provided by 
our algorithm are slightly wider than the intervals suggested by traditional methods when 
single marker tests have extremely high power. However, when the site carrying the 
causal variant is not genotyped, single marker tests becomes less accurate, while our 
method still correctly identifies credible regions covering disease-causing sites. 
According to our simulation results, we obtain comparable mapping accuracy and 
coverage probability, regardless of whether the causal variant is genotyped or not.  These 
results suggest that our algorithm performs robustly when the genotype at causal sites is 
missing.  
4.2 Methods 
We consider a case-control study where we have several thousand individuals, to locate 
candidate regions harboring causal variants in a sequenced region of interest (ROI). 
Suppose we have  cases and  controls, each sequenced in a ROI of K Mbs containing  
variant sites; we denote  as the genotypes of these 2 individuals in  variant sites. We 
denote n  as the observed phenotypes, where o
 = 1  if individual   is an affected 
individual (case), and o
 = 0 if otherwise. 
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At any position O within the ROI, we define  and , the phenotype probability for any 
individual carrying homozygous wild type alleles and for any individual carrying 
homozygous variant type alleles at this position. At a position carrying disease-causal 
variants,  and  at this position are equivalent to the penetrance levels conditional on 
the genotype. At a position independent to the phenotype, true values of  and  are 
both equal to the phenotype prevalence in the target population. 
Under different models of   and , we would like to calculate the joint probability of 
observed phenotypes and genotypes at position O , n, |,  . In Chapter 3, we 
propose an algorithm similar to Zӧllner and Pritchard (2005) or Burkett et al. (2013), 
which calculates n, |,   through integrating over possible genealogies at this 
position O, which is denoted as MN: 
n, |,  = q MN|n|MN, , YMN 
However, the sample space of possible genealogies grows too fast with increased sample 
size , such that this previous MCMC algorithm does not converge in large samples. 
In this Chapter, we separate the entire genealogy MN of any position O into two levels. In 
the lower-end the genealogy, sampled haplotypes have coalesced into   common 
ancestor haplotypes where the value of  is pre-determined in our model. We treat these 
ancient haplotypes as cluster, and approximate the lower-end coalescent process by 
estimating each sampled haplotype’s probability of descending from each cluster. We 
then denote M′N  as the upper-end genealogy of the  clusters as. Since the number of 
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clusters   is pre-selected such that the sample space of genealogies of M′N  does not 
increase with the increased sample size .  
Specifically, we denote z = [W, … W] as the vector of ancient cluster haplotypes, where 
W3 = [W3 , … W/3] represents the allele types of the  variant sites carried in ancient cluster 
{ ({ = 1, 2, … , ). We then denote A, the clusters of origin of sampled individuals, where 
A
{  denotes the probability of individual  ’s (  = 1, … 2 ) first haplotype is a 
descendant from cluster { at site  ( = 1, 2, … , ). 
Consequently, we calculate n, |,  through M′N as follows: 
n, |,  = t z, A| ∙ q MSN|zn|MSN, , , AYM′N ∙ YzYA 
Specifically, we make inference about z, A|  by sampling possible clusters using 
fastPHASE (Scheet and Stephens 2006), such that we approximate n, |,  by: 
n, |,  = 1 < q MSN|zn|MSN, , , AYM′N

s
 
Given estimated   cluster haplotypes z , the posterior probability of upper-end 
genealogies MSN|z can be approximated using the same MCMC algorithm as we 
used to approximate the genealogy of sampled haplotypes in Chapter 3. We then evaluate 
the probability of observed phenotypes conditional on the estimated genealogy, 
n|MSN, , , A  by integrating over possible mutations at every branch on MSN 
(Appendix F). 
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In the present study, we implement our own program, fastTREE, to calculate the joint 
probability of phenotypes and genotypes under different penetrance models, 
n, |, , through estimated genealogy of clusters. We then apply our program to 
Bayesian tests of associations and fine-scale mappings, as described in the following 
subsections. 
4.2.1 Bayesian test of association 
At any position O across the ROI, we propose a method which calculates the posterior 
probability of association (|), as the Bayesian test statistic of phenotypic association 
at this position (Stephens and Balding 2009): 
| = }1 + }, 
where } represents the posterior odds of association: 
} = ~ × 1 − . 
Specifically,  is the prior probability of association. We apply uniform priors across the 
ROI in the present study, such that any position O within the ROI is equally likely to be 
associated with the study phenotype. 
Moreover, ~ is the Bayes factor in favor of association, which evaluate the probability 
of observed phenotype and genotype data under  penetrance model with association 
( ≠ ) over the same probability under model with no association ( = ) as follow: 
~ = n, | ≠ n, | =  
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Under either model, we apply our own algorithm, fastTREE, to calculate n, |,  
through the estimated genealogy of clusters M′N at any tested position O. Therefore, ~ is 
calculated by: 
~ = n, | ≠ n, | =  
= t n, |, YYguvgw
/ t n, |, YYgusgw
 
By definition, higher ~ indicates that the observed phenotype and genotype data is more 
likely following the model with association ( ≠ ), in contrast to the model without 
association ( = ). Consequently, any position O with extremely high values in ~ 
will result in a posterior probability of association close to 1, which can be interpreted as 
strong evidence of association at this position. 
4.2.2 Fine mapping of causal loci 
Similar as testing of associations, we can also apply our algorithm, which calculates the 
joint phenotype and genotype probability through genealogy of clusters, to fine-scale 
mappings of causal variants. 
To begin with, we denote p as the indicator of causal position, where p = O represents 
that a causal mutation is carried at position O in the ROI. In the present study, we assume 
uniform prior probabilities p = O such that any position within the ROI is equally 
likely to be carrying disease-causal mutations. 
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For each position across the ROI, our goal in fine mapping is to calculate each position’s 
posterior probability of carrying disease-causal mutations, conditional on the observed 
genotypes and phenotypes, to identify candidate regions harboring causal variants. By 
Bayes rule, this posterior probability of causality is proportional to: 
p = O|n,  ∝ n, |p = Op = O. 
We calculate n, |p = O by integrating over penetrance levels  and  as described 
in previous subsections: 
n, |p = O = q q n, |, Y


Y


 
Given each penetrance level, n, |,  is calculated through estimated genealogy of 
clusters, M′N, using our algorithm fastTREE. 
Similar as in Chapter 3, we select a set of focal points uniformly distributed across the 
entire ROI. At each focal O , we first calculate n, |p = O  through our estimated 
genealogy of clusters. We then apply a Monte Carlo integration to calculate the posterior 
probability of causality p = O|n,  at each focal point O: 
p = O|n,  ≈ n, |p = O/ < n, |p = 
∈`
. 
4.2.3 Algorithm evaluation 
To evaluate our algorithm performance in mapping of complex trait loci, we first 
simulate a set of 2: haplotypes sequenced in a 1Mbs ROI with 500Kbs flanking region 
on both ends. We then randomly assign these haplotypes into :  diploid individuals. 
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Within the ROI, we randomly pick one variant site as the causal variant based on its 
minor allele frequency. We consider 3 scenarios with different risk allele frequencies, 
1%, 5%, or 20%, to evaluate our algorithm performance. The risk allele effect size is OR 
= 2.0 for the rare risk allele with MAF = 1%. We let OR = 1.5 for the low frequent risk 
allele with MAF = 5%, and OR =1.2 for the common risk allele with MAF = 20%. 
Consequently, we assign a phenotype to each individual conditional on his genotype at 
this causal site under a multiplicative model. We consider different sample sizes in large-
scaled case-control studies, and randomly sample  cases and  controls where  equals 
2,000, 5,000, or 10,000. Under each scenario, we simulate 5 realizations to evaluate our 
algorithm performance. 
To evaluate our algorithm performance in detecting phenotypic associations, we apply 
both our algorithm and the traditional single marker Bayesian approach (BIMBAM; 
Servin and Stephens 2007), to each simulated sample of cases and controls, to identify 
association signals across the ROI. Using BIMBAM, we test for associations at every 
marker individually. While using our algorithm, we make genealogy inferences by 
fastTREE in a set of focal points in every 10kbs, and calculate each focal point’s 
posterior probability of association (|). Under each simulated scenario, we compare 
the median distance between the causal sites and the estimated most likely positions 
(focal points with highest |) in 5 realizations. We then compare our results to the 
distance using BIMBAM, to evaluate our algorithm performance in detecting phenotypic 
associations. 
To evaluate our algorithm performance in fine mapping of complex trait loci, we also 
apply our fine mapping algorithm to each simulated data. Under each simulated scenario, 
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we calculate the median width of 90% credible regions provided by our algorithm, as 
well as the coverage probability, to evaluate our algorithm performance. We also apply 
traditional fine mapping approaches suggested by Servin and Stephens (2007) and 
Stephens and Balding (2009) to each simulated dataset, and calculate the median widths 
of consequent 90% credible regions. We compare the credible region width using our 
algorithm to the width using traditional methods, to evaluate our algorithm performance 
in fine mapping. 
Moreover, to evaluate our algorithm performance when the causal site is not genotyped, 
we mask the genotypes at the exact causal sites, and re-apply our algorithm to each 
simulated dataset. We calculate the same distance in association tests and credible region 
width in fine mappings. We then compare these new results to the previous results to 
illustrate that our method performs robustly when genotypes at causal variant sites are not 
available in study sample. 
4.3 Results 
To evaluate our algorithm performances, we simulate large-scale samples with  cases 
and  controls ( = 2,000, 5,000, or 10,000), each sequenced in a region of 1Mbs with 
500Kbs flanking regions on both sides. Under each sample size, we consider different 
risk allele frequencies with different disease effect sizes: rare risk variants with MAF 
= 1% and effect size OR = 2.0, low frequent risk variants with MAF = 5% and OR 
= 1.5, or common risk variants with MAF = 20% and OR 1.2 . We apply both our 
algorithm and the traditional single marker test based approaches to these simulated 
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datasets, to evaluate our algorithm performance in testing for associations and mapping 
for disease causal variants. 
4.3.1 Testing for associations 
To evaluate our algorithm performance in testing of associations, we make inferences 
about genealogies by fastTREE in a set of focal points per 10Kbs in each simulated 
dataset. We then calculate the posterior probability of associations at each focal point. 
We then compare our results to the results provided by single marker tests using either 
Fisher’s exact test (PLINK; Purcell et al. 2007) or Bayesian approaches (BIMBAM; 
Servin and Stephens 2007). 
To begin with, we illustrate a single realization using 5,000 cases and 5,000 controls, 
while the risk allele to be sought is rare with MAF less than 1% and OR equals 2.0 
(figure 4.2). Using single marker tests, variant sites with smallest p-values in Fisher’s 
exact tests (figure 4.2A) are identical to the sites with greatest posterior probability of 
association ( | ) in Bayesian approaches (figure 4.2B), while both tests provide 
strongest signal at the exact position of the causal variant. Using our algorithm, the 
posterior probability of association at the set of focal points also increases towards the 
causal site, and peaks in the few focal points closest to the causal site. While single 
marker tests provide strong evidence of association at the exact variant site with | 
close 1 (grey dots, figure 4.2B) in this realization, the result using our method provides 
slightly lower | – since we do not test on the causal site directly (figure 4.2B, red 
line). 
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When the causal site is not genotyped, no signal is detected when using single marker 
tests. To illustrate that our algorithm performance with the absence of causal genotypes, 
we mask the causal site, and re-calculate the |  at each focal point to detect any 
evidence of association (figure 4.2B, blue line). Compared to our previous results, we 
obtain almost the same low |  in regions far away from the causal site since the 
missing genotype at the single causal site have no influence on the genealogy estimation 
in these regions. Moreover, we observe the | increases in focal points closer to the 
causal site, and peaks at the position closest to the exact site carrying disease causal 
mutations. Compared to our previous results with genotyped causal site, our algorithm 
identifies the same position with the strongest evidence of association, although the | 
is reduced since the information carried by the causal site is missing in our data. 
In each simulated dataset, we apply both our algorithm and the Bayesian single marker 
tests using BIMBAM (Servin and Stephens 2007) to 5 simulated datasets per scenario, 
and calculate the median distance between the exact causal site and the position showing 
strongest evidence of associations. We then compare these calculated distances using our 
algorithm to the distances using BIMBAM (table 4.1). We also calculate the highest 
posterior probability of association reported in each dataset using our algorithm and using 
BIMBAM, and compare the median value of 5 realizations under each scenario, to 
evaluate under what scenario our method is more powerful than using traditional single 
marker tests. 
Using single marker tests, the results are driven by single marker testing power. When the 
sample size increases, we have higher power to detect the association at the exact causal 
site with higher posterior probability of associations. Under each sample size level, we 
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have higher power to detect low frequent risk variants with MAF = 5% and OR = 1.5, 
rather than rare risk variants with MAF = 1% and OR = 2.0 and common risk variants 
with MAF = 20% and OR = 1.2. Specifically, in smaller sample of 2,000 cases and 2,000 
controls, single marker test is most powerful in detecting low frequent variants with 
moderate effect sizes (MAF = 5%, OR = 1.5), with the highest detected | equals 
0.832 in a site 24Kbs from the exact causal site. The strongest signal is detected with 
higher |, and is detected more closely to the exact positions when we have larger 
sample sizes. With 10,000 cases and 10,000 controls, the median value, we detect a 
posterior probability of association extremely close to 1 at the exact position of the causal 
variant (distance equals 0). 
Using our method, the power to detect phenotypic associations is also increasing with 
increased sample sizes. Moreover, our method is more powerful in detecting rare variant 
associations when risk variant allele frequency is less than 1% with the effect size OR = 
2.0 in these simulated samples of thousands of cases and controls. When we only have 
2,000 cases and 2,000 controls, our algorithm outperforms traditional single marker tests 
with the strongest signal detected closer to the exact position of causal variants – in all 3 
scenarios of allele frequencies. When we have more than 5,000 cases and 5,000 controls, 
although our algorithm correctly detect the strongest association signal within 2 to 3 focal 
points closest to the causal site; it is less powerful than the traditional single marker test 
which directly tests on the exact causal variant site. 
To evaluate if our algorithm performs robustly when the causal site is not genotyped, we 
mask the causal site genotypes, and re-apply our algorithm and the single marker tests to 
each simulated dataset. We illustrate such results in realizations with 5,000 cases and 
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5,000 controls (figure 4.3). Using traditional single marker tests, the distance between the 
causal site and the position with the strongest detected association signal (black dots) 
merely depends on whether neighboring sites under high LD with the causal variant 
outweigh noise markers at random positions across the ROI. Therefore, the variation in 
single marker test performances is very high in the 5 simulated datasets per scenario. In 
contrast, using our algorithm, the strongest signal is always detected within 50Kbs (red 
triangles) from the exact position of the non-genotyped causal variant.  
Moreover, we calculate the median distance between the non-genotyped causal site and 
the focal point with the highest PPA using our method (table 4.2, in parenthesis) under 
each scenario. Compared to previous results, we obtain similar results where the focal 
point with the highest |  only moved by one or two units, such that the median 
distance to the causal site barely changes. 
4.3.2 Fine mapping of causal variants 
Traditionally, association-based fine mapping approaches assume that at least one causal 
variant is covered by the initial set of candidate regions with reported phenotypic 
associations. In contrast, our algorithm does not make such assumption, and can be 
applied directly through our estimated genealogies across the entire ROI, to construct 
credible regions harboring disease causal variants. 
We apply our fine mapping algorithm and the traditional fine mapping approach to 
simulated datasets. Under each scenario, we first calculate the median width of the 90% 
credible regions (table 4.2) in 5 realizations. We then compare our results to the same 
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widths from using traditional fine mapping approaches based on candidate regions with 
detected associations from single marker tests. 
Using traditional approaches, fine mapping accuracy is driven by the power in 
association tests. Therefore, the trend in mapping accuracy across different sample sizes 
and different allele frequencies is identical to the trend in association tests: We obtain 
shorter credible regions with increased sample sizes. And we obtain shortest credible 
regions under each sample size when the causal variant is of low frequent with MAF = 
5% and OR = 1.5. 
Using our fine mapping algorithm, the resulting credible region is also narrowing with 
increased sample size. Under each sample size level, we obtain the narrowest credible 
region when the causal variant is rare (MAF = 1%) with strong effects (OR = 2.0). These 
trends are also identical as the trends in our coalescent-based association tests – since 
both applications are based on the same estimated genealogies. 
Under all scenarios, our algorithm identifies credible regions covering a candidate region 
around 100Kbs. Moreover, our method provides credible regions correctly covering the 
causal variant site in all realizations, indicating that our credible interval may be too 
conservative compared to its nominal credible level. Specifically, when mapping causal 
variants using 2,000 cases and 2,000 controls, our algorithm outperforms traditional 
methods when the causal variant is rare (MAF = 1%) or is of weak effects (OR = 1.2). 
When the sample size is greater than 5,000 cases and 5,000 controls, traditional 
approaches provide more accurate mapping of candidate regions. 
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Moreover, according to our results in association tests, single marker tests do not 
consistently detect association in regions surrounding the causal site. If an association 
study fails to correctly report an initial set of candidate regions covering the causal site, 
the consequent fine mapping will be biased. 
To evaluate if our algorithm provides valid fine mapping results when the causal site is 
not genotyped, we mask the genotypes at causal positions in each simulated dataset, and 
re-apply our algorithm for fine mapping. Consequently, we calculate the new medians of 
credible interval widths under each scenario (table 4.2, in parenthesis). Under all 
scenarios, we observe slightly wider credible regions in scenarios with smaller sample 
sizes, compared to our previous results. Likewise, we observe the same coverage 
probability that our algorithm still correctly identifies candidate regions harboring disease 
causal variants. 
4.3.3 Mapping accuracy when more than one causal variants exist in ROI 
So far we assume that only one causal site is located in the study ROI. In practice, 
multiple risk variants can occur in neighboring regions to affect the study disease. To 
evaluate if our algorithm is capable in identifying more than one risk variants, we 
simulate datasets with 2,000 cases and 2,000 controls where two risk variants exist in the 
1Mbs region of interests. We consider two conditions: either two closely located risk 
variants with mutual distance less than 50Kbs, or two distantly located risk variants 
further than 200Kbs from each other. Likewise, we also consider two scenarios of risk 
allele frequencies: both risk variants are rare with MAF 1% and OR 2.0; or one such rare 
allele with strong effect sizes and one common allele with MAF 20% and OR 1.2. 
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We then apply our algorithm to construct 90% credible regions to evaluate if we have 
correctly covered both risk variants. When two rare risk alleles are closely located, we 
observe one continuous credible region around 100Kbs, which correctly covers both risk 
variant sites (figure 4.4A). In contrast, when two rare alleles are distantly located, our 
credible region covers two discrete sub-regions; each covers one risk variant in a 100Kbs 
area (figure 4.4B). Under the scenario when one common variant and one rare variant are 
closely located from each other (figure 4.4C), the posterior probability curve is skewed to 
the rare variant site as it has stronger effect size to the disease. Our algorithm still 
provides a credible region with similar widths, to correctly identify both risk variants. 
When the common risk variant is distantly located from the rare risk variant (figure 
4.4D), we observes signals on both risk positions, while the estimated posterior 
probability at the rare variant site is about 10 times higher than at the common variant 
site. Although close to the boundary, the common variant is still correctly covered by our 
credible region (figure 4.3D). 
4.4 Discussion 
We have presented and implemented an algorithm to identify complex trait loci through 
estimated genealogies, to enable coalescent-based mapping on studies using large-scaled 
case-control samples. Conditional on observed genotypes, we first make inferences about 
a set of  ancient haplotypes, as common ancestors of sampled individuals, based on a 
clustering algorithm (Scheet and Stephens 2006). We then treat these   common 
ancestors as clusters, and make inferences about this position-specific genealogy of 
clusters. Consequently, we reduce the sampling space of genealogies from a function of 
 82 
 
sample size (2, in haplotypes) to a function of pre-determined number of clusters, . 
We implement this algorithm for genealogy inferences into our own computational tool 
fastTREE. 
Focusing on detecting phenotypic association at any position across the genotyped or 
sequenced ROI, we make inferences about the position-specific genealogy of clusters. 
Conditional on this inferred genealogy, we calculate this position’s Bayes factor (~) in 
favor of association, and then derive the posterior probability of association based on ~, 
at this position. 
Furthermore, we are also able to make causal inferences for fine mapping of compelx 
trait loci, based on the assumption that our ROI contains at least one disease causal 
variant. In a set of focal points across the ROI, we evaluate the inferred genealogies at 
every focal point. We then make Bayesian inferences for causality at these positions, and 
establish credible regions to locate causal variants.  
Compared to traditional coalescent-based approaches for fine mappings, which restrict 
the sample size to a few hundred individuals, our method enables fine mapping in large 
scale case-control studies with up to several ten thousand individuals. Moreover, our 
algorithm can be running in parallel to make genealogy inferences at different positions 
across ROI. Therefore, we are able to apply our method for fine mapping in a sequenced 
ROI of a few Mbs with up to twenty thousand sampled individuals in less than ten days if 
running on 40 to 50 modern computer nodes. 
Compared to traditional fine mapping approaches based on detected associations, our 
method performs more robustly when genotypes at the causal site are missing. Because 
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our method make inferences about genealogies at each position by analyzing genotypes at 
surrounding variants sites jointly, information carried by the missing genotype at one site 
complemented by genotypes within co-inherited haplotype segments. In comparison, 
traditional fine mapping algorithms are based on an initial set of candidate regions with 
detected associations, and calculates individual Bayes factors site-by-site to make causal 
inferences. Based on our simulation, we suggest using our algorithm for fine-scale 
mappings in genomic region of interests where single marker tests are not sufficiently 
powerful in suggesting candidate regions for traditional fine mapping. 
In the present study, we fix the number of clusters   at 400. In practice,   can be 
determined by two factors. First, we want  as high as possible such that our inferred 
genealogy carries more information about the sampled haplotypes’ evolutionary history. 
The upper bound of possible  is then determined by computational burden. Second, we 
want   greater than the number of branches left on the coalescent tree when causal 
mutation occurred in history. Thus the lower bound of  is determined by the disease 
genetic architecture – suppose our goal is to seek some rare causal variant at certain allele 
frequency level (e.g., less than 1%), the lower bound of  is then determined as it must 
be greater than number of branches when all risk allele carriers have met the same 
common ancestor. In coalescent theories, the expected number of branches left in the 
coalescent tree, when all risk allele carriers have coalesced to a common ancestor, can be 
derived sequentially. Overall, the number of  can be pre-selected between the upper and 
lower bound. 
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According to our simulation, our algorithm identifies credible regions covering a 
candidate region around 100Kbs in most scenarios. In practice, this is potentially helpful 
to locate 2 to 3 candidate genes in human genome for follow up studies to understand 
their biological functions. Our algorithm is of interests in studies trying to identify 
complex trait loci using different types of genetic data, such as low-coverage sequencing 
studies or imputation-based studies – in which sites carrying disease causal variants are 
of higher probabilities of not genotyped.  
In present study, we have only considered uniform prior probability of causality across 
the ROI. In practice, more informative priors can be applied based on gene densities or 
annotation of variants, to enhance the efficiency of our algorithm. Other future extensions 
for our algorithm include using mapping of QTLs through estimated genealogies, as well 
as under other generalized phenotypes models. Along with the advances in sequencing 
technologies and the decreasing sequencing costs, we also project more large-scale 
sequencing study samples will be formed in near future. Yet our fine mapping program 
provides a robust and computationally feasible package to identify candidate regions for 
these large-scale studies to improve our understanding about the genetic basis of complex 
diseases. 
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Table 4.1 Estimated posterior probability and the distance between causal sites and 
positions with strongest signal of associations, using single marker tests (BIMBAM) and 
using our algorithm through estimated genealogies (Tree). 
Sample 
size MAF 
BIMBAM Tree 
PPA Dist PPA Dist(*) 
2,000 1% 0.756 45 0.853 15(25) 
2,000 5% 0.832 24 0.788 20(25) 
2,000 20% 0.625 50 0.747 25(30) 
5,000 1% 0.998 2 0.906 15(20) 
5,000 5% 1.000 0 0.887 20(25) 
5,000 20% 1.000 3 0.872 20(25) 
10,000 1% 1.000 0 0.953 15(20) 
10,000 5% 1.000 0 0.946 15(15) 
10,000 20% 1.000 0 0.881 20(25) 
Dist: between positions with strongest signals and causal sites in Kbs. 
PPA: Posterior probability of association. 
*In parenthesis: Distance when causal variant site not genotyped. 
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Table 4.2 Median 90% credible region width in 5 realizations per scenario, using fine 
mapping algorithms based on single marker tests (BIMBAM) and using our algorithm 
through estimated genealogies (Tree). 
Sample 
size MAF 
CI 
BIMBAM Tree(*) 
2,000 1% 122 100(120) 
2,000 5% 76 120(130) 
2,000 20% 140 130(130) 
5,000 1% 35 80(90) 
5,000 5% 24 90(90) 
5,000 20% 42 100(100) 
10,000 1% 8 80(80) 
10,000 5% 5 80(90) 
10,000 20% 22 90(90) 
CI: 90% credible region widths in Kbs 
*In parenthesis: CI width constructed when causal variant site not genotyped. 
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Figure 4.1 Illustration of clustering method when disease mutation occurred prior to the 
formation of clusters. Figure A: genealogy of 16 sampled haplotypes, where disease 
mutation occurred in time when only 3 branches exist. Figure B: genealogy of 5 clusters, 
which reduces the sampling space by ignoring the bottom coalescent details within each 
cluster. 
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Figure 4.2 Test of associations. In figure A, black dots represent the p-values using 
Fisher’s exact tests. In figure B, grey dots are posterior probabilities of associations 
provided by Bayesian approaches for association tests (BIMBAM); while the red line 
indicates the posterior probability of association provided by our algorithm. The true 
causal position is labeled by the green line. 
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Figure 4.3 Distance between the causal site and the position with strongest detected 
associations, when causal site is not genotyped in study samples of 5,000 cases and 5,000 
controls. The black dots represent the distances obtained using single marker tests, while 
the red triangles represent the distances using our algorithm through estimated 
genealogies. The horizontal axis is the physical distances in base-pairs, while the vertical 
axis indicates the three considered allele frequency level: 1%, 5%, and 20% risk alleles.  
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Figure 4.4 Fine mapping results when more than one causal variants exist in the region of 
interest. In figure A, two rare risk variants are closely located with less than 50Kbs. In 
figure B, two rare variants are distantly located further than 200Kbs. In figure C we 
simulate one rare variant and one common risk variant, closely located. In figure D, one 
rare and one common risk variants are distantly located. Posterior curves are represented 
by red solid lines, while the red underlines represent the estimated 90% credible regions. 
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Chapter 5 Conclusion 
5.1 Summary 
Markov chain Monte Carlo (MCMC) algorithms are widely used to analyze high-
dimensional data, and to sample posterior probabilities of interests in modern genetic 
studies. In this dissertation, we have applied an MCMC algorithm on a framework about 
sampling genetically homogeneous sub-samples of affected individuals. We have also 
proposed an MCMC method to model the linkage disequilibrium in genotype data, which 
can be applied to improve the accuracy in haplotype reconstruction, as well as to identify 
candidate regions harboring causal variants of a complex disease. 
In Chapter 2, we propose a novel approach to identify affected individuals carrying the 
same underlying genetic risk variants, which can be applied on studies of any complex 
disease. Using family data with at least one affected individual per family, we first 
analyze the segregation in a large set of observed covariates, to identify subsets of 
covariates correlated to the same risk variants to define subphenotypes. Conditional on 
these covariates subsets, we then calculate each affected individual’s posterior probability 
of belonging to each subtype such that they are more likely to carry the same risk variants 
attributable to this subtype. We further stratify affected individuals based on their subtype 
memberships, and illustrate that using these stratified subsamples of cases provide 
improved power to detect the phenotypic association in relevant loci, compared to the 
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power using all sampled cases. We implement this algorithm into our own program based 
on sibling pair data, CASES. We recommend using CASES to identify genetically 
homogeneous subtypes of affected individuals to improve our understanding of any 
complex disease in follow-up studies. 
In Chapter 3, we propose HMM-enhanced method which improves the modeling of LD 
in coalescent-based estimation of genealogies. Given genotype data, we first make 
inferences about genealogies at different focal points across ROI, and model the LD 
between more distant loci not sharing the same genealogy due to recombination events 
through a HMM algorithm. We then apply this modeling of LD to improve the accuracy 
in haplotype reconstructions. Compared to existing methods, we recommend our model 
in applications for haplotype reconstructions where traditional HMM-based methods 
experience low accuracy due to more complicated population genetic parameters. We 
also apply this coalescent-based LD modeling into case-control studies, to identify 
candidate regions harboring disease causal variants.  We compare our results to 
traditional fine mapping algorithms based on an initial set of candidate loci with detected 
associations, and illustrate that our method outperforms traditional approaches when 
causal site is not directly genotyped and tested. 
In Chapter 4, we implement a clustering method to this coalescent-based algorithm to 
mapping complex trait loci in large-scale studies. We first make inferences about a set of 
common ancestors to the study sample, as a set of clusters. Conditional on the inferred 
ancient haplotypes, we then make inferences about the genealogies of clusters at different 
positions across the ROI to identify candidate regions with causal variants by our own 
program fastTREE. We define a Bayesian approach to test for associations at any 
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position through the inferred genealogies. Based on the assumption that at least one 
causal variant exists within the ROI, we then propose a fine mapping framework through 
the inferred genealogy, to make causal inferences for candidate regions harboring causal 
variants. We evaluate our algorithm under different disease genetic architectures: under 
rare to common causal variants with different effect sizes. We compare our mapping 
results to traditional Bayesian approaches for association tests and fine mappings, and 
illustrate that our algorithm behaves more robustly, and outperforms traditional methods, 
when sample genotypes at causal sites are missing. 
5.2 Relevance and future work 
This dissertation covers MCMC applications on two distinct areas of genetic studies: 
subphenotyping complex diseases to identify genetically homogeneous subsamples of 
cases, and modeling LD through estimated genealogies for reconstructing sample 
haplotypes and mapping complex trait loci. 
We implement our subphenotyping algorithm based on sib-pairs into our own software 
CASES. This sampler will be helpful for practitioners in sequencing studies to prioritize 
individuals more likely to carry specific risk variants, to reduce the sequencing cost. It is 
also helpful in stratifying affected individuals to formulate genetically homogeneous 
subsamples of cases, to improve the power in association studies. Future extension 
includes implementing CASES more generalizable to other family structures and then 
modeling genotypes by kinship coefficients, such that the power to identify genetically 
homogeneous subphenotypes is potentially improved by larger family sizes with parent-
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offspring trios. Meanwhile, CASES currently requires dichotomous diseases, and we 
could further explore the algorithm’s potential in QTL studies by allowing continuous 
phenotype measurements in future works. 
We implement the HMM algorithm onto our own approach similar to TreeLD (Zӧllner 
and Pritchard 2005). Our approach enables making inferences about genealogies based on 
unphased genotype data using high density SNPs or sequencing data. In practice, our 
estimation of genealogies is helpful to improve the accuracy of reconstructing sample 
haplotypes in genomic regions where traditional HMM-based algorithms experience 
limited performances. In practice, practitioners can also apply our approach to make 
inferences about genealogies across a genomic region of interests to identify candidate 
loci harboring disease causal variants. Future extension for our algorithm includes using 
the local information from genealogies to improve genotyping accuracies to identify de 
novo rare variants, as well as identifying recombination hotspots in genomic regions 
through the varying length of shared and non-shared genealogies. Furthermore, we have 
only considered uniform prior probability of causality across the ROI in current study. In 
practice, more informative priors can be applied based on gene densities or annotation of 
variants, to enhance the efficiency of our algorithm. 
When applying our estimated genealogy to identify complex trait loci, we compare our 
algorithm performance to traditional algorithms based on single marker tests. According 
to our results, we suggest using our method to identify candidate regions when single 
marker tests have low power. We would also like to compare our results to other 
advanced strategies, such as collapsing method for rare variant association tests (Li and 
Leal 2008), to further evaluate our algorithm’s potential in different types of studies. 
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We also apply a clustering method to reduce the computational intensity in estimating 
genealogies. We implement this updated method into our own program fastTREE, which 
enables mapping of complex trait loci in large-scale studies with sample sizes up to ten 
thousands. Along with the current advance of sequencing technologies and the trend of 
reduced per individual cost in sequencing studies, we project more large-scale sequencing 
study samples will be formed in near future. Yet our fine mapping program provides a 
robust and computationally feasible package to identify candidate regions for these large-
scale studies to improve our understanding about the genetic basis of complex diseases. 
  
 96 
 
Appendix 
A: Metropolis-coupled MCMC setup. 
Genotype probability in sib-pairs: For each sib-pair , we model the joint genotype 
probability as: 

| = 1 
3|33  
For each variant locus {, 
3|3 is calculated by integrating over possible identity by 
descent (IBD) status, where IBD ∈ {0,1,2}: 

3|3 = 1 
3|3, ~X = O~X = O
2
Ns
 
The prior probabilities of IBD equals 0, 1, or 2 are 0.25, 0.5, and 0.25, respectively. 
The spike and slab prior: For the covariate , the probability of affected by risk variant 
in subtype {  is denoted as 3 = 3 ≠ 0 , is arbitrarily chosen between 0 and 1. 
Conditional on it is effective, the effect size is uniformly distributed in (–log5, log5). 
Therefore, the entire prior probability is: 
=3 ≠ 0? ∙ =1 − 3? + =3 = 0? ∙ 3/2#$%5 
We use the same prior on between-covariate-effects. 
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Parallel Markov chains: We run   Markov chains with different initial status in 
parallel. For each chain  , the total likelihood is powered by a “heat”: P =
[1 + ℎ ∙  − 1]* < 1, where the heat-factor h is arbitrarily chosen from 0 to 1. 
Chain switching: Let K  be the likelihood in chain  . We randomly choose 2 
consecutive chains per one thousand rounds in MCMC, and copy the information from 
chain ^ to chain  with probability L	(1, [) where [ = (K K⁄ )*. 
MCMC updates: In each Markov chain, we update all sib-pairs' genotype based on 
Metropolis-Hasting (M-H) algorithm in each round. We randomly choose one 3 from 
all effect sizes in every 20 rounds of the MCMC, and update this effect based on the M-H 
algorithm. We update the between covariate effects using the same mechanism. For allele 
frequency, randomly pick locus { per 50 rounds, and update allele frequency 3 based on 
the conjugate posterior ~(M + 1, 2 − M − 1) distribution, where M is the total risk allelic 
type counts in all sibling 1s (or 2s), and 2–M is the total counts for non-risk alleles. 
B: Discriminate risk variant carriers from non-carriers 
When there are two subtypes ( = 2) affected by two risk variants, CASES gives 2 
vectors of inferred posterior probability about carrying variant 1 and 2. 
To determine if carriers from different risk variants can be discriminated from each other, 
we compare the difference between pair-wised distance within carriers and among any 
pair of individuals in the figure below. The horizontal axis represents effect sizes on 
covariates ranging from 1.0 to 2.0, and the vertical axis is the difference in pair-wised 
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distances. The red (or green) line is the difference between within carriers of variant 1 (or 
2) and within all samples, and the black line is such difference between within all carriers 
and within all samples. 
 
In general, the mean pair-wised distances within either variant 1 or 2 carriers are shorter 
than the overall pair-wised distance. The distance is further shortened along with the 
increased covariate effect sizes. In other words, individuals carrying the same variant are 
more likely to formulate a cluster and stay close with each other with respect to the 
inferred posterior probability of carrying each subtype. In addition, the mean distance for 
pairs of individuals with one carrying variant 1 and the other carrying variant 2 is also 
shorter than the overall mean pair-wised distance, because carriers are either clustered at 
the high end of inferred subtype 1 or 2. 
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C: Power comparison under different effect sizes. 
We compare the under different risk variant effects to the phenotype in the figure below. 
The underlying risk variant affects 10 covariates, whose allele frequency is 5%. The 
effect size to the phenotype is 1.0, 1.5 or 2.0. The horizontal axis represents effect sizes 
on covariates ranging from 1.0 to 2.0, and the vertical axis is power under significance 
level A = 5 × 10*7. 
 
In general, power is increasing along with the covariate effect sizes. When the risk 
variant is truly affecting the phenotype, the power using our stratified sample 
outperforms the power using full samples. More importantly, when the effect size on 
phenotype is OR 1.0 (no association), the power curve using stratified subtype of cases 
fluctuates around the nominal significance level – indicating that our algorithm does not 
inflate the false discovery rate. 
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D: Testing power, multiple risk variants affecting the same covariates. 
To evaluate if more than one risk variants affecting the same set of covariates would 
affect our algorithm performance, we consider scenarios where 10 covariates are affected 
by risk variant 1, while 0, 5, or 10 out of these 10 covariates are also affected by another 
risk variant 2. We summarize the power to detect phenotypic association at variant site 1 
below. Since the true number of subtypes () is unknown, we compared the power under 
 = 1 and  = 2 model in figure A and B, respectively. The horizontal axis represents 
effect sizes on covariates ranging from 1.0 to 2.0, and the vertical axis is power under 
significance level A = 5 × 10*7. 
When risk variant 2 affect no covariate, the power to detect association at variant site 1 is 
identical to the previous single locus model with 10 covariates under  = 1 . 
Alternatively, when we specify  = 2, CASES correctly identifies the second underlying 
variant affects no covariate. Thus, the power is only slightly reduced due to the extra 
parameters to be estimated, compared to the K=1 model. 
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When risk variant 2 affect 5 out of the 10 covariates affected by risk variant 1, we 
observe reduced power in both  = 1 and  = 2 models, due to the more complicated 
correlation structures between covariates. Specifically, the  = 2  model correctly 
specifies the number of underlying risk variants, and thus outperforms the  = 1 model 
which treats total variation unexplained by the single risk variant as between-covariate 
correlation. 
When risk variant 2 affects all 10 covariates as variant 1 does, we cannot distinguish 
these two variants. Instead, these two variants are identified as one variant with elevated 
allele frequency under the  = 1 model. Since the resulting stratified cases are more 
likely to be carriers of either risk variant 1 or 2, we still observe increased risk allele 
frequency and improved testing power using this stratified subsample. Under  = 2 
model, our algorithm struggles to distinguish the following 2 possibilities: 1. Two 
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subtypes affected by two variants are represented by exactly the same covariates. 2. One 
subtype, affected by a more common risk variant, is represented by all 10 covariates; 
while the other subtype affected by another variant is not represented in any covariate. 
Due to the choice of the spike-and-slab prior, we put more weights on effect sizes equal 
0. Thus, our algorithm converges to the second possibility such that similar testing power 
as in the  = 1 model. 
Overall, we see different specification of  results in different algorithm performance. In 
reality, we do not know the true number of subtypes carried in our sample. Thus we 
always want to specify the "best" value of  in CASES, to make our algorithm most 
efficient. We suggest a sequential procedure for model selection below. 
E: Selection of  , the number of subtypes. 
In practice, we do not know the true number of subtypes due to underlying risk variants 
carried in our sample. We would like to choose the best value of  to identify individuals 
carrying risk variants most efficiently. 
Essentially, how to determine the value of  is a model selection problem. We begin 
from the extreme case where underlying genetic variants affect only covariates (no 
subtype). Then the posterior probability of the phenotypic effect should be identical to its 
prior spike and slab distribution, which peaks at 0. If so, we have evidence that no 
underlying genetic variant is affecting the phenotype. 
Similarly, when we set  greater than the true number of underlying risk variants in our 
model, some effect size to the phenotypes will always show the same spike at 0 since 
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these pseudo, excessive factors are in fact unrelated to the disease. Indeed, we suggest 
that when using CASES, one could determine  under a sequential manner: 
We start running CASES from  ′ = 1, and check the histogram on the phenotypic effect 
size to see if it peaks at 0. If so, stop CASES since no heritable subtype can be identified. 
If not, we increase ′  by 1 and re-run CASES and evaluate all modeled variants’ 
phenotypic effects. We increase ’ iteratively until we see at least one variant’s effect 
size estimate shows the spike at 0. Accordingly, a possibly reasonable choice about the 
number of risk sites is then  = ′ − 1, which can be used in the follow-up inference 
and stratification. 
F: Posterior probability of phenotypes given genealogy. 
Given any penetrance level   and   at each focal point O , we propose possible 
occurrence of causal mutation on every possible branch on the genealogy of the  
clusters M′N. There are 2 − 2 possible positions to allow for mutations, we define an 
indicator ~ =   to represent that the disease mutation is occurred on branch   ( =
1, …2 − 2), whose prior probability (~ = ) is proportional to the branch length. 
(n|M′N, , , A) = <(n|M′N, , , A, ~ = )(~ = ) 
Conditional on each proposed mutation on M′N , the genotype at focal point O of each 
ancient haplotype is fully determined. We use ℎN
()  and ℎN
(2)  to denote the two allele 
types of individual  at this position. We then define the probability that individual  is a 
case as follows: 
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(
)({, {2) = (o
 = 1)ℎN
(), ℎN
(2)+ = (e
(w)Te())/2 ∙ (2*e
(w)*e())/2
 
where the two alleles are inherited from ancient cluster {  and {2 . Similarly, the 
probability that individual  is a control is  1 − (
)({, {2). 
Given the cluster of origin probabilities in A, we then sum over all possible cluster of 
origins, to calculate the marginal phenotype probability if individual  is a case: 
< < (
)({, {2)

3s
∙ AN
(2)({2) ∙ AN
()({)

3ws
 
We calculate the marginal phenotype probability for each control similarly, such that the 
joint phenotype probability of all individuals is: 
(n|M′N, , , A, ~ = ) 
= 1 < < (
)({, {2)

3s
∙ AN
(2)({2) ∙ AN
()({)

3ws
∈ji
 
∙1 < < [1 − (
)({, {2)]

3s
∙ AN
(2)({2) ∙ AN
()({)

3ws
∈jh
 
Consequently, we integrate over mutations occurring on all possible branches to calculate 
the joint phenotype probability conditional on genealogies: 
(n|M′N, , , A) = <(n|M′N, , , A, ~ = )(~ = ) 
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